<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VIBATIV- telavancin hydrochlorideÂ injection, powder, lyophilized, for solutionÂ </strong><br>Theravance Biopharma Antibiotics, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VIBATIV<span class="Sup">Â®</span> (telavancin) safely and effectively. See full prescribing information for VIBATIV.<br>VIBATIV<span class="Sup">Â®</span> (telavancin) for injection, for intravenous use<br>Initial U.S. Approval: 2009
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNINGS</span></h1>
<h1 class="Warning"></h1>
<ul class="Disc">
<li><span class="Bold">Patients with pre-existing moderate/severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl â‰¤50 mL/min)who were treated with VIBATIV for hospital-acquired bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>/ventilator-associated bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> had increased mortality observed versus vancomycin. Use of VIBATIV in patients with pre-existing moderate/severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl â‰¤50 mL/min) should be considered only when the anticipated benefit to the patient outweighs the potential risk. (<a href="#s16">5.1</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span>: New onset or worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has occurred. Monitor renal function in all patients. (<a href="#s18">5.3</a>)</span></li>
<li><span class="Bold">Women of childbearing potential should have a serum pregnancy test prior to administration of VIBATIV. (<a href="#s19">5.4</a>, <a href="#s40">8.1</a>)</span></li>
<li>
<span class="Bold">Avoid use of VIBATIV during pregnancy unless potential benefit to the patient outweighs potential risk to the fetus</span><span class="Bold">. (<a href="#s40">8.1</a>)</span>
</li>
<li><span class="Bold">Adverse developmental outcomes observed in 3 animal species at clinically relevant doses raise concerns about potential adverse developmental outcomes in humans. (<a href="#s40">8.1</a>)</span></li>
</ul>
</div></div>
<div>
<div><p class="Highlighta"><span class="Bold">To reduce the development of drug-resistant bacteria and maintain the effectiveness of VIBATIV and other antibacterial drugs VIBATIV should only be used to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</span> (<a href="#s3">1</a>)
 </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Warnings and Precautions (12/2014)</span> </p>
<p class="Highlighta"><span class="Bold">Contraindications (12/2014)</span> </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNINGS</span></h1>
<h1 class="Warning"></h1>
<ul class="Disc">
<li><span class="Bold">Patients with pre-existing moderate/severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl â‰¤50 mL/min)who were treated with VIBATIV for hospital-acquired bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>/ventilator-associated bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> had increased mortality observed versus vancomycin. Use of VIBATIV in patients with pre-existing moderate/severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl â‰¤50 mL/min) should be considered only when the anticipated benefit to the patient outweighs the potential risk. (<a href="#s16">5.1</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span>: New onset or worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has occurred. Monitor renal function in all patients. (<a href="#s18">5.3</a>)</span></li>
<li><span class="Bold">Women of childbearing potential should have a serum pregnancy test prior to administration of VIBATIV. (<a href="#s19">5.4</a>, <a href="#s40">8.1</a>)</span></li>
<li>
<span class="Bold">Avoid use of VIBATIV during pregnancy unless potential benefit to the patient outweighs potential risk to the fetus</span><span class="Bold">. (<a href="#s40">8.1</a>)</span>
</li>
<li><span class="Bold">Adverse developmental outcomes observed in 3 animal species at clinically relevant doses raise concerns about potential adverse developmental outcomes in humans. (<a href="#s40">8.1</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">VIBATIV is a lipoglycopeptide antibacterial drug indicated for the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adult patients caused by designated susceptible bacteria:
 </p>
<ul class="Disc">
<li>Complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (cSSSI) (<a href="#s4">1.1</a>)
</li>
<li>Hospital-acquired and ventilator-associated bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (HABP/VABP) caused by susceptible isolates of <span class="Italics">Staphylococcus aureus</span>. VIBATIV should be reserved for use when alternative treatments are not suitable.(<a href="#s5">1.2</a>)
</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc">
<li>Complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (cSSSI):</li>
<li>10 mg/kg by IV infusion over 60 minutes every 24 hours for 7 to 14 days (<a href="#s7">2.1</a>)
</li>
<li>Dosage adjustment in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#s9">2.3</a>)
</li>
<li>Hospital-acquired and ventilator-associated bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (HABP/VABP):</li>
<li>10 mg/kg by IV infusion over 60 minutes every 24 hours for 7 to 21 days (<a href="#s8">2.2</a>)
</li>
<li>Dosage adjustment in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#s9">2.3</a>)
</li>
</ul>
<table width="100%">
<col align="left" width="50.333%">
<col align="left" width="45.867%">
<col align="left" width="3.800%">
<tfoot><tr class="First Last"><td align="justify" colspan="3" valign="top"><p class="Footnote Highlighta"><span class="Sup">a</span>Calculate using the Cockcroft-Gault formula and ideal body weight (IBW). Use actual body weight if &lt; IBW. (<a href="#s59">12.3</a>)
 </p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<span class="Bold">Creatinine Clearance</span><span class="Bold"><span class="Sup">a</span></span><span class="Bold">(CrCl)<br>(mL/min)</span>
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom"><span class="Bold">VIBATIV Dosage Regimen</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">&gt;50
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">10 mg/kg every 24 hours
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">30-50
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">7.5 mg/kg every 24 hours
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">10-&lt;30
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">10 mg/kg every 48 hours
</td>
</tr>
</tbody>
</table>
<p class="Highlighta">Insufficient data are available to make a dosing recommendation for patients with CrClÂ &lt;10 mL/min, including patients on hemodialysis.
 </p>
</div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Single-use vials containing either 250 or 750 mg telavancin. (<a href="#s13">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Dis">
<li>Intravenous Unfractionated Heparin Sodium (<a href="#e14">4.1</a>, <a href="#s20">5.5</a>, <a href="#s36">7.1</a>)
</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to VIBATIV. (<a href="#e15">4.2</a>, <a href="#s21">5.6</a>, <a href="#s34">6.2</a>)
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Decreased efficacy among patients treated for skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with moderate/severe pre-existing <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: Consider these data when selecting antibacterial therapy for patients with baseline CrCl â‰¤50 mL/min. (<a href="#s17">5.2</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>: Serious and potentially fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, may occur after first or subsequent doses. VIBATIV should be used with caution in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to vancomycin. (<a href="#s21">5.6</a>, <a href="#s34">6.2</a>)
</li>
<li>Infusion-related reactions: Administer VIBATIV over at least 60Â minutes to minimize infusion-related reactions. (<a href="#s22">5.7</a>)
</li>
<li>
<span class="Italics">Clostridium difficile</span>-associated disease: May range from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Evaluate if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs. (<a href="#s23">5.8</a>)
</li>
<li>Coagulation test interference: Telavancin interferes with some laboratory coagulation tests, including <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, international normalized ratio, and <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span>. (<a href="#s20">5.5</a>, <a href="#s36">7.1</a>)</li>
<li>QTc prolongation: Avoid use in patients at risk. Use with caution in patients taking drugs known to prolong the QT interval. (<a href="#s26">5.10</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reaction (â‰¥10% of patients treated with VIBATIV) in the HABP/VABP trials is <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; in the cSSSI trials, the most common adverse reactions (â‰¥10% of patients treated with VIBATIV) include: <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and foamy urine. (<a href="#s28">6.1</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Theravance Biopharma US, Inc. at 1-855-633-8479 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div><div>
<div></div>
<div></div>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy: Based on animal data, may cause fetal harm. Pregnancy registry available. (<a href="#s40">8.1</a>)
</li>
<li>Pediatric patients: Safety and efficacy not demonstrated. (<a href="#s49">8.4</a>)
</li>
</ul></div>
<div><div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 12/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNINGS
</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 HABP/VABP
</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Hospital-Acquired Bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>/Ventilator-Associated Bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> (HABP/VABP)
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Preparation and Administration
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Intravenous Unfractionated Heparin Sodium
</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to VIBATIV
</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Increased Mortality in Patients with HABP/VABP and Pre-existing Moderate to Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (CrClâ‰¤50 mL/min)
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Decreased Clinical Response in Patients with cSSSI and Pre-existing Moderate/Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (CrClâ‰¤50 mL/min)
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span>
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Pregnant Women and Women of Childbearing Potential
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Coagulation Test Interference
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>
</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Infusion-Related Reactions
</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="Italics">Clostridium difficile</span>-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Development of Drug-Resistant Bacteria
</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 QTc Prolongation
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Drug-Laboratory Test Interactions
</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics
</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics
</a></h2>
<h2><a href="#section-11.4" class="toc">12.4 Microbiology
</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology
</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL TRIALS
</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 HABP/VABP
</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES
</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s2"></a><a name="section-1"></a><p></p>
<h1>WARNINGS
</h1>
<ul class="Square">
<li>
<span class="Bold">Patients with pre-existing moderate/severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl â‰¤ 50 mL/min) who were treated with VIBATIV for hospital-acquired bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>/ventilator-associated bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> had increased mortality observed versus vancomycin.  Use of VIBATIV in patients with pre-existing moderate/severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrClâ‰¤ 50 mL/min) should be considered only when the anticipated benefit to the patient outweighs the potential risk [see
</span><span class="Bold Italics">Warnings and Precautions </span><span class="Bold Italics">(<a href="#s16">5.1</a>)</span><span class="Bold">].</span>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span>: New onset or worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has occurred. Monitor renal function in all patients </span><span class="Bold">[see
</span><span class="Bold Italics">Warnings and Precautions </span><span class="Bold Italics">(<a href="#s18">5.3</a>)</span><span class="Bold">].</span>
</li>
<li>
<span class="Bold">Women of childbearing potential should have a serum pregnancy test prior to administration of VIBATIV [see
</span><span class="Bold Italics">Warnings and Precautions (<a href="#s19">5.4</a>), Use in Specific Populations (<a href="#s40">8.1</a>)</span><span class="Bold">].</span>
</li>
<li>
<span class="Bold">Avoid use of VIBATIV during pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus [see
</span><span class="Bold Italics">Warnings and Precautions (<a href="#s19">5.4</a>), Use in Specific Populations (<a href="#s40">8.1</a>)</span><span class="Bold">].</span>
</li>
<li>
<span class="Bold">Adverse developmental outcomes observed in 3 animal species at clinically relevant doses raise concerns about potential adverse developmental outcomes in humans [see
</span><span class="Bold Italics">Warnings and Precautions (<a href="#s19">5.4</a>), Use in Specific Populations (</span><span class="Bold Italics"><a href="#s40">8.1</a></span><span class="Bold Italics">)</span><span class="Bold">]</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s3"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of VIBATIV and other antibacterial drugs, VIBATIV should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
</p>
<p>Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram-negative organisms.
</p>
<p>Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to telavancin.  VIBATIV may be initiated as empiric therapy before results of these tests are known.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
</h2>
<p class="First">VIBATIV is indicated for the treatment of adult patients with complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (cSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: <span class="Italics">Staphylococcus aureus</span> (including methicillin-susceptible and -resistant isolates), <span class="Italics">Streptococcus pyogenes</span>, <span class="Italics">Streptococcus agalactiae</span>, <span class="Italics">Streptococcus anginosus</span> group (includes <span class="Italics">S. anginosus, S.Â intermedius,</span> and <span class="Italics">S. constellatus)</span>, or <span class="Italics">Enterococcus faecalis</span> (vancomycin-susceptible isolates only).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-1.2"></a><p></p>
<h2>1.2 HABP/VABP
</h2>
<p class="First">VIBATIV is indicated for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (HABP/VABP), caused by susceptible isolates of <span class="Italics">Staphylococcus aureus</span> (including methicillin-susceptible and -resistant isolates). VIBATIV should be reserved for use when alternative treatments are not suitable.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s6"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
</h2>
<p class="First">The recommended dosing for VIBATIV is 10 mg/kg administered over a 60-minute period in patients â‰¥18 years of age by intravenous infusion once every 24 hours for 7 to 14 days. The duration of therapy should be guided by the severity and site of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the patient's clinical progress.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Hospital-Acquired Bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>/Ventilator-Associated Bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> (HABP/VABP)
</h2>
<p class="First">The recommended dosing for VIBATIV is 10 mg/kg administered over a 60-minute period in patients â‰¥18 years of age by intravenous infusion once every 24 hours for 7 to 21 days. The duration of therapy should be guided by the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the patient's clinical progress.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">Because telavancin is eliminated primarily by the kidney, a dosage adjustment is required for patients whose creatinine clearance is â‰¤50 mL/min, as listed in <a href="#t1">TableÂ 1</a> [see <span class="Italics">Clinical Pharmacology (<a href="#s59">12.3</a>)</span>].
</p>
<a name="t1"></a><table width="100%">
<caption><span>TableÂ 1: Dosage Adjustment in Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</span></caption>
<col align="left" width="50.333%">
<col align="left" width="45.867%">
<col align="left" width="3.800%">
<tfoot><tr class="First Last"><td align="justify" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">a</span>Calculate using the Cockcroft-Gault formula and ideal body weight (IBW).  Use actual body weight if it is less than IBW. (<span class="Italics"><a href="#s59">12.3</a></span>)
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<span class="Bold">Creatinine Clearance</span><span class="Bold"><span class="Sup">a</span></span><span class="Bold">(CrCl)<br>(mL/min)</span>
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom"><span class="Bold">VIBATIV Dosage Regimen</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">&gt;50
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">10 mg/kg every 24 hours
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">30-50
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">7.5 mg/kg every 24 hours
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">10-&lt;30
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">10 mg/kg every 48 hours
</td>
</tr>
</tbody>
</table>
<p>There is insufficient information to make specific dosage adjustment recommendations for patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (CrClÂ &lt;10Â mL/min), including patients undergoing hemodialysis.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Preparation and Administration
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-2.4.1"></a><p></p>
<p class="First"><span class="Underline">250 mg vial</span>: Reconstitute the contents of a VIBATIV 250 mg vial with <span class="Bold">15</span> mL of 5% Dextrose Injection, USP; Sterile Water for Injection, USP; or 0.9% Sodium Chloride Injection, USP. The resultant solution has a concentration of 15 mg/mL (total volume of approximately 17.0Â mL).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-2.4.2"></a><p></p>
<p class="First"><span class="Underline">750 mg vial</span>: Reconstitute the contents of a VIBATIV 750 mg vial with <span class="Bold">45</span> mL of 5% Dextrose Injection, USP; Sterile Water for Injection, USP; or 0.9% Sodium Chloride Injection, USP. The resultant solution has a concentration of 15 mg/mL (total volume of approximately 50.0Â mL).
</p>
<p>To minimize foaming during product reconstitution, allow the vacuum of the vial to pull the diluent from the syringe into the vial. Do not forcefully inject the diluent into the vial. Do not forcefully shake the vial and do not shake final infusion solution.
</p>
<p>The following formula can be used to calculate the volume of reconstituted VIBATIV solution required to prepare a dose:
</p>
<dl>
<dt>Â 
</dt>
<dd>
<span class="Bold">Telavancin dose (mg) = 10 mg/kg or 7.5 mg/kg x patient weight (in kg)</span> (see <a href="#t1">Table 1</a>)<br><br>
</dd>
<dt>Â 
</dt>
<dd>
<span class="Bold">Volume of reconstituted solution (mL) =
</span><span class="Bold Underline">Telavancin dose (mg)<br></span><span class="Bold">Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â 15 mg/mL</span>
</dd>
</dl>
<p>For doses of 150 to 800 mg, the appropriate volume of reconstituted solution must be further diluted in 100 to 250Â mL prior to infusion. Doses less than 150 mg or greater than 800Â mg should be further diluted in a volume resulting in a final concentration of 0.6Â to 8Â mg/mL. Appropriate infusion solutions include: 5% Dextrose Injection, USP; 0.9% Sodium Chloride Injection, USP; or Lactated Ringer's Injection, USP. The dosing solution should be administered by intravenous infusion over a period of 60 minutes.
</p>
<p>Reconstitution time is generally under 2 minutes, but can sometimes take up to 20Â minutes. Mix thoroughly to reconstitute and check to see if the contents have dissolved completely. Parenteral drug products should be inspected visually for particulate matter prior to administration. Discard the vial if the vacuum did not pull the diluent into the vial.
</p>
<p>Since no preservative or bacteriostatic agent is present in this product, aseptic technique must be used in preparing the final intravenous solution. Studies have shown that the reconstituted solution in the vial should be used within 12 hours when stored at room temperature or within 7 days under refrigeration at 2 to 8Â°C (36 to 46Â°F). The diluted (dosing) solution in the infusion bag should be used within 12 hours when stored at room temperature or used within 7 days when stored under refrigeration at 2 to 8Â°C (36 to 46Â°F). However, the total time in the vial plus the time in the infusion bag should not exceed 12Â hours at room temperature and 7 days under refrigeration at 2 to 8Â°C (36Â toÂ 46Â°F). The diluted (dosing) solution in the infusion bag can also be stored at -30 to -10Â°C (-22 to 14Â°F) for up to 32 days.
</p>
<p>VIBATIV is administered intravenously. Because only limited data are available on the compatibility of VIBATIV with other IV substances, additives or other medications should not be added to VIBATIV single-use vials or infused simultaneously through the same IV line. If the same intravenous line is used for sequential infusion of additional medications, the line should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> before and after infusion of VIBATIV with 5% Dextrose Injection, USP; 0.9% Sodium Chloride Injection, USP; or Lactated Ringer's Injection, USP.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s13"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">VIBATIV is supplied in single-use vials containing either 250 or 750 mg telavancin as a sterile, lyophilized powder.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s14"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="e14"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Intravenous Unfractionated Heparin Sodium
</h2>
<p class="First">Use of intravenous unfractionated heparin sodium is contraindicated with VIBATIV administration because the <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> (aPTT) test results are expected to be artificially prolonged for 0 to 18 hours after VIBATIV administration [see <span class="Italics">Warnings and Precautions (<a href="#s20">5.5</a>) and Drug Interactions (<a href="#s36">7.1</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e15"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to VIBATIV
</h2>
<p class="First">VIBATIV is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to telavancin.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s15"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Increased Mortality in Patients with HABP/VABP and Pre-existing Moderate to Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (CrClâ‰¤50 mL/min)
</h2>
<p class="First">In the analysis of patients (classified by the treatment received) in the two combined HABP/VABP trials with pre-existing moderate/severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrClâ‰¤50 mL/min), all-cause mortality within 28 days of starting treatment was 95/241 (39%) in the VIBATIV group, compared with 72/243 (30%) in the vancomycin group.Â  All-cause mortality at 28 days in patients without pre-existing moderate/severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl&gt;50 mL/min) was 86/510 (17%) in the VIBATIV group and 92/510 (18%) in the vancomycin group. Therefore, VIBATIV use in patients with baseline CrClâ‰¤50 mL/min should be considered only when the anticipated benefit to the patient outweighs the potential risk [see <span class="Italics">Adverse Reactions, Clinical Trials Experience (<a href="#s28">6.1</a>)</span> and <span class="Italics">Clinical Trials, HABP/VABP (<a href="#s88">14.2</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Decreased Clinical Response in Patients with cSSSI and Pre-existing Moderate/Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (CrClâ‰¤50 mL/min)
</h2>
<p class="First">In a subgroup analysis of the combined cSSSI trials,clinical cure rates in the VIBATIV-treated patients were lower in patients with baseline CrCl â‰¤50 mL/min compared with those with CrCl&gt;50 mL/min (<a href="#t2">TableÂ 2</a>). A decrease of this magnitude was not observed in vancomycin-treated patients.  Consider these data when selecting antibacterial therapy for use in patients with cSSSI and with baseline moderate/severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.
</p>
<a name="t2"></a><table width="100%">
<caption><span>TableÂ 2: Clinical Cure by Pre-existing <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> â€“ Clinically Evaluable Population
</span></caption>
<col align="left" width="23.708%">
<col align="left" width="38.146%">
<col align="left" width="38.146%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">VIBATIV<br>% (n/N)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Vancomycin<br>% (n/N)</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle"><span class="Bold">cSSSI Trials</span></td>
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">CrCl&gt;50 mL/min
</td>
<td class="Botrule Rrule" align="center" valign="middle">87.0% (520/598)
</td>
<td class="Botrule Rrule" align="center" valign="middle">85.9% (524/610)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">CrCl â‰¤50 mL/min
</td>
<td class="Botrule Rrule" align="center" valign="middle">67.4% (58/86)
</td>
<td class="Botrule Rrule" align="center" valign="middle">82.7% (67/81)
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span>
</h2>
<p class="First">In both the HABP/VABP trials and the cSSSI trials, renal adverse events were more likely to occur in patients with baseline comorbidities known to predispose patients to <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">kidney dysfunction</span> (pre-existing <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>). The renal adverse event rates were also higher in patients who received concomitant medications known to affect kidney function (e.g., non-steroidal anti-inflammatory drugs, ACE inhibitors, and loop diuretics).
</p>
<p>Monitor renal function (i.e., serum creatinine, creatinine clearance) in all patients receiving VIBATIV. Values should be obtained prior to initiation of treatment, during treatment (at 48- to 72-hour intervals or more frequently, if clinically indicated), and at the end of therapy. If renal function decreases, the benefit of continuing VIBATIV versus discontinuing and initiating therapy with an alternative agent should be assessed [see <span class="Italics">Dosage and Administration (<a href="#s6">2</a>), Adverse Reactions (<a href="#s27">6</a>),</span> and <span class="Italics">Clinical Pharmacology (<a href="#s59">12.3</a>)</span>].
</p>
<p>In patients with renal dysfunction, accumulation of the solubilizer hydroxypropyl-beta-cyclodextrin can occur [see <span class="Italics">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (<a href="#s51">8.6</a>)</span> and <span class="Italics">Clinical Pharmacology (<a href="#s59">12.3</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Pregnant Women and Women of Childbearing Potential
</h2>
<p class="First">Avoid use of VIBATIV during pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus. VIBATIV caused adverse developmental outcomes in 3 animal species at clinically relevant doses. This raises concern about potential adverse developmental outcomes in humans.
</p>
<p>Women of childbearing potential should have a serum pregnancy test prior to administration of VIBATIV. If not already pregnant, women of childbearing potential should use effective contraception during VIBATIV treatment [see <span class="Italics">Use in Specific Populations (<a href="#s40">8.1</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Coagulation Test Interference
</h2>
<p class="First">Although telavancin does not interfere with coagulation, it interfered with certain tests used to monitor coagulation (<a href="#t3">TableÂ 3</a>), when conducted using samples drawn 0 to 18 hours after VIBATIV administration for patients being treated once every 24 hours. Blood samples for these coagulation tests should be collected as close as possible prior to a patient's next dose of VIBATIV. Blood samples for coagulation tests unaffected by VIBATIV may be collected at any time [see <span class="Italics">DrugÂ Interactions (<a href="#s36">7.1</a>)</span>].
</p>
<p>For patients who require aPTT monitoring while being treated with VIBATIV, a non phospholipid dependent coagulation test such as a Factor Xa (chromogenic) assay or an alternative anticoagulant not requiring aPTT monitoring may be considered.</p>
<a name="t3"></a><table width="100%">
<caption><span>TableÂ 3: Coagulation Tests Affected and Unaffected by Telavancin
</span></caption>
<col align="left" width="45.250%">
<col align="left" width="54.750%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Affected by Telavancin</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Unaffected by Telavancin</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time/international normalized ratio<br><span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">Activated partial thromboplastin time</span><br>Activated clotting time<br>Coagulation based factor X activity assay
</td>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4208541" conceptname="Thrombin time">Thrombin time</span><br>Whole blood (Lee-White) clotting time<br>Platelet aggregation study<br>Chromogenic anti-factor Xa assay<br>Functional (chromogenic) factor X activity assay<br><span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">Bleeding time</span><br>D-dimer<br>Fibrin degradation products
</td>
</tr>
</tbody>
</table>
<p>No evidence of increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk has been observed in clinical trials with VIBATIV. Telavancin has no effect on platelet aggregation. Furthermore, no evidence of hypercoagulability has been seen, as healthy subjects receiving VIBATIV have normal levels of D-dimer and fibrin degradation products.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>
</h2>
<p class="First">Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, may occur after first or subsequent doses. Discontinue VIBATIV at first sign of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. Telavancin is a semi-synthetic derivative of vancomycin; it is unknown if patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to vancomycin will experience cross-reactivity to telavancin. VIBATIV should be used with caution in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to vancomycin [see <span class="Italics">Postmarketing Experience (<a href="#s34">6.2</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Infusion-Related Reactions
</h2>
<p class="First">VIBATIV is a lipoglycopeptide antibacterial agent and should be administered over a period of 60 minutes to reduce the risk of infusion-related reactions. Rapid intravenous infusions of the glycopeptide class of antimicrobial agents can cause â€œRed-man Syndromeâ€?-like reactions including: <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> of the upper body, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Stopping or slowing the infusion may result in cessation of these reactions.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="Italics">Clostridium difficile</span>-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-5.8.1"></a><p></p>
<p class="First"><span class="Italics">Clostridium difficile-</span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with nearly all antibacterial agents and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the flora of the colon and may permit overgrowth of <span class="Italics">C.Â difficile</span>.
</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hyper-toxin-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, since these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary because CDAD has been reported to occur more than 2Â months after the administration of antibacterial agents.
</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C.Â difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Development of Drug-Resistant Bacteria
</h2>
<p class="First">Prescribing VIBATIV in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
</p>
<p>As with other antibacterial drugs, use of VIBATIV may result in overgrowth of nonsusceptible organisms, including fungi. Patients should be carefully monitored during therapy. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, appropriate measures should be taken.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-5.10"></a><p></p>
<h2>5.10 QTc Prolongation
</h2>
<p class="First">In a study involving healthy volunteers, doses of 7.5 and 15 mg/kg of VIBATIV prolonged the QTc interval [see <span class="Italics">ClinicalÂ Pharmacology (<a href="#s57">12.2</a>)</span>]. Caution is warranted when prescribing VIBATIV to patients taking drugs known to prolong the QT interval. Patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>, known prolongation of the QTc interval, uncompensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or severe <span class="product-label-link" type="condition" conceptid="4184746" conceptname="Left ventricular hypertrophy">left ventricular hypertrophy</span> were not included in clinical trials of VIBATIV. Use of VIBATIV should be avoided in patients with these conditions.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s27"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<p class="First">The following serious adverse reactions are also discussed elsewhere in the labeling:
</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> [see <span class="Italics">Warnings and Precautions (<a href="#s18">5.3</a>)</span>]
</li>
<li>Infusion-related reactions [see <span class="Italics">Warnings and Precautions (<a href="#s22">5.7</a>)</span>]
</li>
<li>
<span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> [see <span class="Italics">Warnings and Precautions (<a href="#s23">5.8</a>)</span>]
</li>
</ul>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></p>
<p>The two Phase 3 cSSSI clinical trials (Trial 1 and Trial 2) for VIBATIV included 929 adult patients treated with VIBATIV at 10 mg/kg IV once daily. The mean age of patients treated with VIBATIV was 49Â years (range 18-96). There was a slight male predominance (56%) in patients treated with VIBATIV, and patients were predominantly Caucasian (78%).
</p>
<p>In the cSSSI clinical trials, &lt;1% (8/929) patients who received VIBATIV died and &lt;1% (8/938) patients treated with vancomycin died. Serious adverse events were reported in 7% (69/929) of patients treated with VIBATIV and most commonly included renal, respiratory, or cardiac events. Serious adverse events were reported in 5% (43/938) of vancomycin-treated patients, and most commonly included cardiac, respiratory, or infectious events. Treatment discontinuations due to adverse events occurred in 8% (72/929) of patients treated with VIBATIV, the most common events being <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (~1% each). Treatment discontinuations due to adverse events occurred in 6% (53/938) of vancomycin-treated patients, the most common events being <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (~1% each).
</p>
<p>The most common adverse events occurring in â‰¥10% of VIBATIV-treated patients observed in the VIBATIV Phase 3 cSSSI trials were <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and foamy urine.
</p>
<p><a href="#t4">TableÂ 4</a> displays the incidence of treatment-emergent adverse drug reactions reported in â‰¥2% of patients treated with VIBATIV possibly related to the drug.
</p>
<a name="t4"></a><table width="100%">
<caption><span>TableÂ 4: Incidence of Treatment-Emergent Adverse Drug Reactions Reported in â‰¥2% of VIBATIV or Vancomycin Patients Treated in cSSSI Trial 1 and Trial 2
</span></caption>
<col align="left" width="53.749%">
<col align="left" width="23.126%">
<col align="left" width="23.126%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="center" valign="bottom">Â 
</th>
<th class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">VIBATIV<br>(N=929)</span></th>
<th class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Vancomycin<br>(N=938)</span></th>
</tr></thead>
<tfoot><tr class="First Last"><td align="justify" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">*</span> Described as a metallic or soapy taste.
</p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left" valign="top">Body as a Whole
</td>
<td class="Botrule" align="center" valign="top">Â 
</td>
<td class="Botrule Rrule" align="center" valign="top">Â 
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">4%
</td>
<td class="Botrule Rrule" align="center" valign="bottom">2%
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">Digestive System
</td>
<td class="Botrule" align="center" valign="top">Â 
</td>
<td class="Botrule Rrule" align="center" valign="top">Â 
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">27%
</td>
<td class="Botrule Rrule" align="center" valign="bottom">15%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">14%
</td>
<td class="Botrule Rrule" align="center" valign="bottom">7%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">7%
</td>
<td class="Botrule Rrule" align="center" valign="bottom">8%
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">Metabolic and Nutritional
</td>
<td class="Botrule" align="center" valign="top">Â 
</td>
<td class="Botrule Rrule" align="center" valign="top">Â 
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">Nervous System
</td>
<td class="Botrule" align="center" valign="top">Â 
</td>
<td class="Botrule Rrule" align="center" valign="top">Â 
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste disturbance</span><span class="Sup">*</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">33%
</td>
<td class="Botrule Rrule" align="center" valign="bottom">7%
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">Renal System
</td>
<td class="Botrule" align="center" valign="top">Â 
</td>
<td class="Botrule Rrule" align="center" valign="top">Â 
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Foamy urine
</td>
<td class="Botrule Rrule" align="center" valign="bottom">13%
</td>
<td class="Botrule Rrule" align="center" valign="bottom">3%
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">HABP/VABP</span></p>
<p>Two randomized, double-blind Phase 3 trials (Trial 1 and Trial 2) for VIBATIV included 1,503 adult patients treated with VIBATIV at 10 mg/kg IV once daily or vancomycin at 1 g IV twice daily. The mean age of patients treated with VIBATIV was 62Â years (range 18-100). In patients treated with VIBATIV, 69% of the patients were white and 65% were male. In the combined VIBATIV group, 29% were VAP and 71% were HAP patients.
</p>
<p><a href="#t5">TableÂ 5</a> summarizes <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> using Kaplan-Meier estimates at Day 28 as stratified by baseline creatinine clearance categorized into four groups. Patients with pre-existing moderate/severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrClâ‰¤50 mL/min) who were treated with VIBATIV for HABP/VABP had increased mortality observed versus vancomycin in both the trials.
</p>
<a name="t5"></a><table width="100%">
<caption><span>TableÂ 5: 28-Day Mortality (Kaplan-Meier Estimates) Stratified by Baseline Creatinine Clearance â€” All-Treated Analysis Population
</span></caption>
<col align="left" width="11.584%">
<col align="left" width="14.327%">
<col align="left" width="15.626%">
<col align="left" width="14.327%">
<col align="left" width="14.327%">
<col align="left" width="15.626%">
<col align="left" width="14.184%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="bottom"><span class="Bold">CrCl (mL/min)</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="middle"><span class="Bold">Trial 1</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="middle"><span class="Bold">Trial 2</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">VIBATIV</span><br><span class="Bold">N (%)</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">Vancomycin</span><br><span class="Bold">N (%)</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">Difference</span><br><span class="Bold">(95% CI)</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">VIBATIV</span><br><span class="Bold">N (%)</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">Vancomycin</span><br><span class="Bold">N (%)</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">Difference</span><br><span class="Bold">(95% CI)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">&gt;80
</td>
<td class="Botrule Rrule" align="center" valign="middle">143 (12.2%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">152 (14.1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">-1.8<br>(-9.6, 6.0)
</td>
<td class="Botrule Rrule" align="center" valign="middle">181 (10.5%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">181 (18.7%)
</td>
<td class="Botrule Rrule" align="center" valign="top">-8.2<br>(-15.5, -0.9)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">&gt;50-80
</td>
<td class="Botrule Rrule" align="center" valign="middle">88 (27.4%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">88 (17.7%)
</td>
<td class="Botrule Rrule" align="center" valign="top">9.7<br>(-2.7, 22.1)
</td>
<td class="Botrule Rrule" align="center" valign="middle">96 (25.6%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">90 (27.1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">-1.5<br>(-14.4, 11.3)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">30-50
</td>
<td class="Botrule Rrule" align="center" valign="middle">80 (34.7%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">83 (23.1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">11.5<br>(-2.5, 25.5)
</td>
<td class="Botrule Rrule" align="center" valign="middle">62 (27.7%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">68 (23.7%)
</td>
<td class="Botrule Rrule" align="center" valign="top">4.0<br>(-11.1, 19.1)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">&lt;30
</td>
<td class="Botrule Rrule" align="center" valign="middle">61 (44.3%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">51 (37.3%)
</td>
<td class="Botrule Rrule" align="center" valign="top">7.0<br>(-11.2, 25.2)
</td>
<td class="Botrule Rrule" align="center" valign="middle">38 (61.1%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">41 (42.1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">19.0<br>(-2.9, 40.8)
</td>
</tr>
</tbody>
</table>
<p>Serious adverse events were reported in 31% of patients treated with VIBATIV and 26% of patients who received vancomycin. Treatment discontinuations due to adverse events occurred in 8% (60/751) of patients who received VIBATIV, the most common events being <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4008859" conceptname="Prolonged QT interval">electrocardiogram QTc interval prolonged</span> (~1% each). Treatment discontinuations due to adverse events occurred in 5% (40/752) of vancomycin-patients, the most common events being <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span> and multi-organ failure (&lt;1%).
</p>
<p><a href="#t6">TableÂ 6</a> displays the incidence of treatment-emergent adverse drug reactions reported in â‰¥Â 5% of HABP/VABP patients treated with VIBATIV possibly related to the drug.
</p>
<a name="t6"></a><table width="100%">
<caption><span>TableÂ 6: Incidence of Treatment-Emergent Adverse Drug Reactions Reported  in â‰¥5% of VIBATIV or Vancomycin Patients Treated in HABP/VABP Trial 1 and Trial 2
</span></caption>
<col align="left" width="54.333%">
<col align="left" width="22.267%">
<col align="left" width="23.400%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">VIBATIV<br>(N=751)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Vancomycin<br>(N=752)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">Â  Â  Â  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">5%
</td>
<td class="Botrule Rrule" align="center" valign="bottom">4%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">Â  Â  Â  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">5%
</td>
<td class="Botrule Rrule" align="center" valign="bottom">4%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="bottom">Â  Â  Â  <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Renal Failure Acute</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">5%
</td>
<td class="Botrule Rrule" align="center" valign="bottom">4%
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Bold Italics">Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></p>
<p>In cSSSI trials, the incidence of renal adverse events indicative of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (increased serum creatinine, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, and/or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>) was 30/929 (3%) of VIBATIV-treated patients compared with 10/938 (1%) of vancomycin-treated patients. In 17 of the 30 VIBATIV-treated patients, these adverse events had not completely resolved by the end of the trials, compared with 6 of the 10 vancomycin-treated patients. Serious adverse events indicative of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> occurred in 11/929 (1%) of VIBATIV-treated patients compared with 3/938 (0.3%) of vancomycin-treated patients. Twelve patients treated with VIBATIV discontinued treatment due to adverse events indicative of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared with 2 patients treated with vancomycin.
</p>
<p>Increases in serum creatinine to 1.5 times baseline occurred more frequently among VIBATIV-treated patients with normal baseline serum creatinine (15%) compared with vancomycin-treated patients with normal baseline serum creatinine (7%).
</p>
<p>Fifteen of 174 (9%) VIBATIV-treated patients â‰¥65Â years of age had adverse events indicative of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared with 16 of 755Â patients (2%) &lt;65 years of age [see <span class="Italics">Use in Specific Populations (<a href="#s50">8.5</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Bold Italics">Hospital-Acquired and Ventilator-Associated Bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></span></p>
<p>In the HABP/VABP trials, the incidence of renal adverse events (increased serum creatinine, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, and/or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>) was 10% for VIBATIV vs. 8% for vancomycin. Of the patients who had at least one renal adverse event, 54% in each treatment group recovered completely, recovered with sequelae, or were improving from the renal AE at the last visit.Â  Three percent ofÂ VIBATIV-treated patients and 2% ofÂ vancomycin-treated patients experienced at least one serious renal adverse event. Renal adverse events resulted in discontinuation of study medication in 14 VIBATIV-treated patients (2%) and 7 vancomycin-treated patients (1%).
</p>
<p>Increases in serum creatinine to 1.5 times baseline occurred more frequently among VIBATIV-treated patients (16%) compared with vancomycin-treated patients (10%).
</p>
<p>Forty-four of 399 (11.0%) VIBATIV-treated patients â‰¥65Â years of age had adverse events indicative of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared with 30 of 352Â patients (8%) &lt;65 years of age [see <span class="Italics">Use in Specific Populations (<a href="#s50">8.5</a>)</span>].
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience
</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of VIBATIV. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
</p>
<p>Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported after first or subsequent doses of VIBATIV, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>. It is unknown if patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to vancomycin will experience cross-reactivity to telavancin. [see <span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> (<a href="#s21">5.6</a>)</span>]
</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s35"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<div class="Section" data-sectionCode="34074-5">
<a name="s36"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Drug-Laboratory Test Interactions
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-7.1.1"></a><p></p>
<p class="First"><span class="Underline">Effects of Telavancin on Coagulation Test Parameters</span></p>
<p>Telavancin binds to the artificial phospholipid surfaces added to common anticoagulation tests, thereby interfering with the ability of the coagulation complexes to assemble on the surface of the phospholipids and promote clotting <span class="Italics">in vitro</span>. These effects appear to depend on the type of reagents used in commercially available assays. Thus, when measured shortly after completion of an infusion of VIBATIV, increases in the PT, INR, aPTT, and ACT have been observed. These effects dissipate over time, as plasma concentrations of telavancin decrease.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-7.1.2"></a><p></p>
<p class="First"><span class="Underline">Urine Protein Tests</span></p>
<p>Telavancin interferes with urine qualitative dipstick protein assays, as well as quantitative dye methods (e.g., pyrogallol red-molybdate). However, microalbumin assays are not affected and can be used to monitor urinary protein excretion during VIBATIV treatment.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s39"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s40"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s41"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Underline">Teratogenic Effects: Pregnancy Category C</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-8.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Pregnancy Exposure Registry</span></p>
<p>There is a pregnancy registry that monitors pregnancy outcomes in women exposed to VIBATIV during pregnancy. Physicians are encouraged to register pregnant patients, or pregnant women may enroll themselves in the VIBATIV pregnancy registry by calling 1-855-633-8479.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-8.1.1.2"></a><p></p>
<p class="First"><span class="Italics">Fetal Risk Summary</span></p>
<p>All pregnancies have a background risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> (about 3%), pregnancy loss (about 15%), or other adverse outcomes regardless of drug exposure.
</p>
<p>There are no data on VIBATIV use in pregnant women. In 3 animal species, VIBATIV exposure during pregnancy at clinically relevant doses caused reduced fetal weights and increased rates of digit and <span class="product-label-link" type="condition" conceptid="134741" conceptname="Congenital anomaly of limb">limb malformations</span> in offspring. These data raise concern about potential adverse developmental outcomes in humans (see <span class="Italics"><a href="#s45">Data</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-8.1.1.3"></a><p></p>
<p class="First"><span class="Italics">Clinical Considerations</span></p>
<p>Given the lack of human data and the risks suggested by animal data, avoid using VIBATIV in pregnant women unless the benefits to the patient outweigh the potential risks to the fetus.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-8.1.1.4"></a><p></p>
<p class="First"><span class="Italics">Data</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-8.1.1.4.1"></a><p></p>
<p class="First">Human Data
</p>
<p>There are no data on human pregnancies exposed to VIBATIV.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-8.1.1.4.2"></a><p></p>
<p class="First">Animal Data
</p>
<p>In embryo-fetal development studies in rats, rabbits, and minipigs, telavancin demonstrated the potential to cause limb and skeletal malformations when given intravenously during the period of organogenesis at doses up to 150, 45, or 75 mg/kg/day, respectively. These doses resulted in exposure levels approximately 1- to 2-fold the human exposure (AUC) at the maximum clinical recommended dose. Malformations observed at &lt;1% (but absent or at lower rates in historical or concurrent controls), included brachymelia (rats and rabbits), <span class="product-label-link" type="condition" conceptid="4162283" conceptname="Syndactyly">syndactyly</span> (rats, minipigs), <span class="product-label-link" type="condition" conceptid="4169990" conceptname="Adactyly">adactyly</span> (rabbits), and <span class="product-label-link" type="condition" conceptid="74740" conceptname="Polydactyly">polydactyly</span> (minipigs). Additional findings in rabbits included flexed front paw and absent ulna, and in the minipigs included misshapen digits and deformed front leg. Fetal body weights were decreased in rats.
</p>
<p>In a prenatal/perinatal development study, pregnant rats received intravenous telavancin at up to 150 mg/kg/day (approximately the same AUC as observed at the maximum clinical dose) from the start of organogenesis through lactation. Offspring showed decreases in fetal body weight and an increase in the number of stillborn pups. Brachymelia was also observed. Developmental milestones and fertility of the pups were unaffected.
</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s48"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">It is not known whether telavancin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when VIBATIV is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s49"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">The safety and effectiveness of VIBATIV in pediatric patients has not been studied.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s50"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">Of the 929 patients treated with VIBATIV at a dose of 10 mg/kg once daily in clinical trials of cSSSI, 174 (19%) were â‰¥65 years of age and 87 (9%) were â‰¥75Â years of age. In the cSSSI trials, lower clinical cure rates were observed in patients â‰¥65 years of age compared with those &lt;65 years of age. Overall, treatment-emergent adverse events occurred with similar frequencies in patients â‰¥65 (75% of patients) and &lt;65 years of age (83% of patients). Fifteen of 174 (9%) patients â‰¥65 years of age treated with VIBATIV had adverse events indicative of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared with 16 of 755 (2%) patients &lt;65 years of age [see <span class="Italics">Warnings and Precautions (<a href="#s18">5.3</a>), Clinical Trials (<a href="#s87">14.1</a>)</span>].
</p>
<p>Of the 749 HABP/VABP patients treated with VIBATIV at a dose of 10 mg/kg once daily in clinical trials of HABP/VABP, 397 (53%) were â‰¥65 years of age and 230 (31%) were â‰¥75Â years of age. Treatment-emergent adverse events as well as <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and other serious adverse events occurred more often in patients â‰¥65 years of age than in those &lt;65Â years of age in both treatment groups.
</p>
<p>Telavancin is substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in this age group.
</p>
<p>The mean plasma AUC values of telavancin were similar in healthy young and elderly subjects. Dosage adjustment for elderly patients should be based on renal function [see <span class="Italics">Dosage and Administration (<a href="#s6">2</a>), Clinical Pharmacology (<a href="#s59">12.3</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">The HABP/VABP and cSSSI trials included patients with normal renal function and patients with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients with underlying renal dysfunction or risk factors for renal dysfunction had a higher incidence of renal adverse events [see <span class="Italics">Warnings and Precautions (<a href="#s18">5.3</a>)</span>].
</p>
<p>In the HABP/VABP studies higher mortality rates were observed in the VIBATIV-treated patients with baseline CrClâ‰¤50 mL/min. Use of VIBATIV in patients with pre-existing moderate/severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should be considered only when the anticipated benefit to the patient outweighs the potential risk [see <span class="Italics">Warnings and Precautions</span> (<span class="Italics"><a href="#s16">5.1</a></span>)].
</p>
<p>VIBATIV-treated patients in the cSSSI studies with baseline creatinine clearance â‰¤50Â mL/min had lower clinical cure rates. Consider these data when selecting antibacterial therapy in patients with baseline moderate/severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl â‰¤50 mL/min) [see <span class="Italics">Warnings and Precautions (<a href="#s17">5.2</a></span>)].
</p>
<p>Dosage adjustment is required in patients with â‰¤50 mL/min <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <span class="Italics">Dosage and Administration (<a href="#s6">2</a></span>)]. There is insufficient information to make specific dosage adjustment recommendations for patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (CrClÂ &lt;10Â mL/min), including patients receiving hemodialysis [see <span class="Italics">Overdosage (<a href="#s53">10</a>), ClinicalÂ Pharmacology (<a href="#s59">12.3</a>)</span>].
</p>
<p>Hydroxypropyl-beta-cyclodextrin is excreted in urine and may accumulate in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Serum creatinine should be closely monitored and, if renal toxicity is suspected, an alternative agent should be considered [<span class="Italics">see Warnings and Precautions (<a href="#s18">5.3</a>), Clinical Pharmacology (<a href="#s59">12.3</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">The HABP/VABP and cSSSI trials included patients with normal hepatic function and with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. No dosage adjustment is recommended in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [see <span class="Italics">Clinical Pharmacology (<a href="#s59">12.3</a>)</span>].
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s53"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<p class="First">In the event of overdosage, VIBATIV should be discontinued and supportive care is advised with maintenance of glomerular filtration and careful monitoring of renal function. Following administration of a single dose of VIBATIV 7.5 mg/kg to subjects with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, approximately 5.9% of the administered dose of telavancin was recovered in the dialysate following 4 hours of hemodialysis. However, no information is available on the use of hemodialysis to treat an overdosage [see <span class="Italics">Clinical Pharmacology (<a href="#s59">12.3</a>)</span>].
</p>
<p>The clearance of telavancin by continuous venovenous hemofiltration (CVVH) was evaluated in an <span class="Italics">in vitro</span> study [see <span class="Italics">Nonclinical Toxicology (<a href="#s85">13.2</a>)</span>]. Telavancin was cleared by CVVH and the clearance of telavancin increased with increasing ultrafiltration rate. However, the clearance of telavancin by CVVH has not been evaluated in a clinical study; thus, the clinical significance of this finding and use of CVVH to treat an overdosage is unknown.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s54"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">VIBATIV contains telavancin hydrochloride (<a href="#fig1">Figure 1</a>), a lipoglycopeptide antibacterial that is a synthetic derivative of vancomycin.
</p>
<p>The chemical name of telavancin hydrochloride is vancomycin, N3''-[2-(decylamino)ethyl]-29-[[(phosphono-methyl)-amino]-methyl]- hydrochloride. Telavancin hydrochloride has the following chemical structure:
</p>
<p><a name="fig1"></a>Figure 1: Telavancin Hydrochloride
</p>
<div class="Figure">
<a name="f01"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c09655ea-7af5-4443-a769-86e416214f59&amp;name=vib02-0018-01.jpg">
</div>
<p>Telavancin hydrochloride is an off-white to slightly colored amorphous powder with the empirical formula C<span class="Sub">80</span>H<span class="Sub">106</span>Cl<span class="Sub">2</span>N<span class="Sub">11</span>O<span class="Sub">27</span>Pâ€¢xHCl (where x = 1 to 3) and a free-base molecular weight of 1755.6. It is highly lipophilic and slightly soluble in water.
</p>
<p>VIBATIV is a sterile, preservative-free, white to slightly colored lyophilized powder containing telavancin hydrochloride (equivalent to either 250 mg or 750 mg of telavancin as the free base) for intravenous use. The inactive ingredients are Hydroxypropylbetadex, Ph. Eur (hydroxypropyl-beta-cyclodextrin) (2500 mg per 250Â mg telavancin, 7500 mg per 750 mg telavancin), mannitol (312.5 mg per 250 mg telavancin, 937.5 mg per 750 mg telavancin), and sodium hydroxide and hydrochloric acid used in minimal quantities for pH adjustment. When reconstituted, it forms a clear to slightly colored solution with a pH of 4.5 (4.0 to 5.0).
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s55"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s56"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">Telavancin is an antibacterial drug [see <span class="Italics">Clinical Pharmacology (<a href="#s74">12.4</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s57"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics
</h2>
<p class="First">The antimicrobial activity of telavancin appears to best correlate with the ratio of area under the concentration-time curve to <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (AUC/MIC) for S<span class="Italics">taphylococcus aureus</span> based on animal models of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Exposure-response analyses of the clinical trials support the dose of 10 mg/kg every 24 hours.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Underline">Cardiac Electrophysiology</span></p>
<p>The effect of telavancin on cardiac repolarization was assessed in a randomized, double-blind, multiple-dose, positive-controlled, and placebo-controlled, parallel study (n=160). Healthy subjects received VIBATIV 7.5 mg/kg, VIBATIV 15 mg/kg, positive control, or placebo infused over 60 minutes once daily for 3 days. Based on interpolation of the data from VIBATIV 7.5 mg/kg and 15 mg/kg, the mean maximum baseline-corrected, placebo-corrected QTc prolongation at the end of infusion was estimated to be 12-15 msec for VIBATIV 10Â mg/kg and 22 msec for the positive control (<a href="#t7">TableÂ 7</a>). By 1 hour after infusion the maximum QTc prolongation was 6-9Â msec for VIBATIV and 15 msec for the positive control.
</p>
<a name="t7"></a><table width="100%">
<caption><span>TableÂ 7: Mean and Maximum QTcF Changes from Baseline Relative to Placebo
</span></caption>
<col align="left" width="25.333%">
<col align="left" width="37.000%">
<col align="left" width="37.667%">
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center" valign="bottom">Â 
</th>
<th class="Botrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<span class="Bold">QTcF</span><span class="Bold"><span class="Sup">1
</span></span><span class="Bold">Change from Baseline</span>
</th>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">1</span> Fridericia corrected
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">2</span> Upper CL from a 2-sided 90% CI on difference from placebo (msec)
</p></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â 
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">Mean<br>(Upper 90% Confidence Limit</span><span class="Bold"><span class="Sup">2</span></span><span class="Bold">)<br>msec</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Maximum<br>(Upper 90% Confidence Limit)<br>msec</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">VIBATIV 7.5 mg/kg
</td>
<td class="Botrule Rrule" align="center" valign="top">4.1 (7)
</td>
<td class="Botrule Rrule" align="center" valign="top">11.6 (16)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">VIBATIV 15 mg/kg
</td>
<td class="Botrule Rrule" align="center" valign="top">4.6 (8)
</td>
<td class="Botrule Rrule" align="center" valign="top">15.1 (20)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Positive Control
</td>
<td class="Botrule Rrule" align="center" valign="top">9.5 (13)
</td>
<td class="Botrule Rrule" align="center" valign="top">21.6 (26)
</td>
</tr>
</tbody>
</table>
<p>ECGs were performed prior to and during the treatment period in patients receiving VIBATIV 10 mg/kg in 3 cSSSI studies to monitor QTc intervals. In these trials, 214Â of 1029 (21%) patients allocated to treatment with VIBATIV and 164 of 1033 (16%) allocated to vancomycin received concomitant medications known to prolong the QTc interval and known to be associated with definite or possible risk of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>. The incidence of QTc prolongation &gt;60 msec was 1.5% (15 patients) in the VIBATIV group and 0.6% (6Â patients) in the vancomycin group. Nine of the 15 VIBATIV patients received concomitant medications known to prolong the QTc interval and definitely or possibly associated with a risk of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, compared with 1 of the 6 patients who received vancomycin. A similar number of patients in each treatment group (&lt;1%) who did not receive a concomitant medication known to prolong the QTc interval experienced a prolongation &gt;60 msec from baseline. In a separate analysis, 1 patient in the VIBATIV group and 2 patients in the vancomycin group experienced QTcÂ &gt;500Â msec. No cardiac adverse events were ascribed to prolongation of the QTc interval. In the Phase 3 HABP/VABP studies, the incidence of QTc prolongation &gt;60 msec or mean value &gt;500 msec was 8% (52 patients) in the telavancin group and 7% (48 patients) in the vancomycin group.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s59"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<p class="First">The mean pharmacokinetic parameters of telavancin (10 mg/kg) after a single and multiple 60-minute intravenous infusions (10 mg/kg every 24 hours) are summarized in <a href="#t8">TableÂ 8</a>.
</p>
<a name="t8"></a><table width="100%">
<caption><span>TableÂ 8: Pharmacokinetic Parameters of Telavancin in Healthy Adults, 10 mg/kg
</span></caption>
<col align="left" width="34.422%">
<col align="left" width="32.789%">
<col align="left" width="32.789%">
<tfoot>
<tr class="First"><td align="justify" colspan="3" valign="middle"><p class="First Footnote">Â  Â  Â  Â  Â  Â  C<span class="Sub">max</span> maximum plasma concentration
</p></td></tr>
<tr><td align="justify" colspan="3" valign="middle"><p class="First Footnote">Â  Â  Â  Â  Â  Â  AUC area under concentration-time course
</p></td></tr>
<tr><td align="justify" colspan="3" valign="middle"><p class="First Footnote">Â  Â  Â  Â  Â  Â  t<span class="Sub">1/2</span> terminal elimination half-life
</p></td></tr>
<tr><td align="justify" colspan="3" valign="middle"><p class="First Footnote">Â  Â  Â  Â  Â  Â  Cl clearance
</p></td></tr>
<tr><td align="justify" colspan="3" valign="middle"><p class="First Footnote">Â  Â  Â  Â  Â  Â  V<span class="Sub">ss</span> apparent volume of distribution at steady state
</p></td></tr>
<tr class="Last"><td align="justify" colspan="3" valign="middle"><p class="First Footnote">Â  Â  Â  Â  Â  Â  <span class="Sup">1</span> Data not available
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle">Â 
</td>
<td class="Rrule" align="center" valign="middle"><span class="Bold">Single Dose</span></td>
<td class="Rrule" align="center" valign="middle"><span class="Bold">Multiple Dose</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">(n=42)</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">(n=36)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">C<span class="Sub">max</span> (mcg/mL)
</td>
<td class="Botrule Rrule" align="center" valign="middle">93.6 Â± 14.2
</td>
<td class="Botrule Rrule" align="center" valign="middle">108 Â± 26
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">AUC<span class="Sub">0-âˆž</span> (mcgÂ·hr/mL)
</td>
<td class="Botrule Rrule" align="center" valign="middle">747 Â± 129
</td>
<td class="Botrule Rrule" align="center" valign="middle">--<span class="Sup">1</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">AUC<span class="Sub">0-24h</span> (mcgÂ·hr/mL)
</td>
<td class="Botrule Rrule" align="center" valign="middle">666 Â± 107
</td>
<td class="Botrule Rrule" align="center" valign="middle">780 Â± 125
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">t<span class="Sub">1/2</span> (hr)
</td>
<td class="Botrule Rrule" align="center" valign="middle">8.0 Â± 1.5
</td>
<td class="Botrule Rrule" align="center" valign="middle">8.1 Â± 1.5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Cl (mL/hr/kg)
</td>
<td class="Botrule Rrule" align="center" valign="middle">13.9 Â± 2.9
</td>
<td class="Botrule Rrule" align="center" valign="middle">13.1 Â± 2.0
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">V<span class="Sub">ss</span> (mL/kg)
</td>
<td class="Botrule Rrule" align="center" valign="middle">145 Â± 23
</td>
<td class="Botrule Rrule" align="center" valign="middle">133 Â± 24
</td>
</tr>
</tbody>
</table>
<p>In healthy young adults, the pharmacokinetics of telavancin administered intravenously were linear following single doses from 5 to 12.5 mg/kg and multiple doses from 7.5 to 15 mg/kg administered once daily for up to 7 days. Steady-state concentrations were achieved by the third daily dose.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Distribution</span></p>
<p>Telavancin binds to human plasma proteins, primarily to serum albumin, in a concentration-independent manner. The mean binding is approximately 90% and is not affected by renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
</p>
<p>Concentrations of telavancin in pulmonary epithelial lining fluid (ELF) and alveolar macrophages (AM) were measured through collection of bronchoalveolar lavage fluid at various times following administration of VIBATIVÂ 10Â mg/kg once daily for 3Â days to healthy adults.  Telavancin concentrations in ELF and AM exceeded the MIC<span class="Sub">90</span> for <span class="Italics">S. aureus</span> (0.5Â mcg/mL) for at least 24 hours following dosing.
</p>
<p>Concentrations of telavancin in skin <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> fluid were 40% of those in plasma (AUC<span class="Sub">0-24hr</span>Â ratio) after 3 daily doses of 7.5 mg/kg VIBATIV in healthy young adults.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Metabolism</span></p>
<p>No metabolites of telavancin were detected in <span class="Italics">inÂ vitro</span> studies using human liver microsomes, liver slices, hepatocytes, and kidney S9 fraction. None of the following recombinant CYP 450 isoforms were shown to metabolize telavancin in human liver microsomes: CYP 1A2, 2C9, 2C19, 2D6, 3A4, 3A5, 4A11. The clearance of telavancin is not expected to be altered by inhibitors of any of these enzymes.
</p>
<p>In a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance study in male subjects using radiolabeled telavancin, 3 hydroxylated metabolites were identified with the predominant metabolite (THRX-651540) accounting for &lt;10% of the radioactivity in urine and &lt;2% of the radioactivity in plasma. The metabolic pathway for telavancin has not been identified.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Excretion</span></p>
<p>Telavancin is primarily eliminated by the kidney. In a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance study, approximately 76% of the administered dose was recovered from urine and &lt;1% of the dose was recovered from feces (collected up to 216 hours) based on total radioactivity.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Specific Populations</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Italics">Geriatric Patients</span></p>
<p>The impact of age on the pharmacokinetics of telavancin was evaluated in healthy young (range 21-42 years) and elderly (range 65-83 years) subjects. The mean CrCl of elderly subjects was 66 mL/min. Age alone did not have a clinically meaningful impact on the pharmacokinetics of telavancin [see <span class="Italics">Use in Specific Populations (<a href="#s50">8.5</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s65"></a><a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Italics">Pediatric Patients</span></p>
<p>The pharmacokinetics of telavancin in patients less than 18 years of age have not been studied.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s66"></a><a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Italics">Gender</span></p>
<p>The impact of gender on the pharmacokinetics of telavancin was evaluated in healthy male (n=8) and female (n=8) subjects. The pharmacokinetics of telavancin were similar in males and females. No dosage adjustment is recommended based on gender.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s67"></a><a name="section-11.3.8"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The pharmacokinetics of telavancin were evaluated in subjects with normal renal function and subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> following administration of a single dose of telavancin 7.5 mg/kg (n=28). The mean AUC<span class="Sub">0-âˆž</span> values were approximately 13%, 29%, and 118% higher for subjects with CrCl &gt;50 to 80 mL/min, CrCl 30 to 50 mL/min, and CrClÂ &lt;30Â mL/min, respectively, compared with subjects with normal renal function. Dosage adjustment is required in patients with CrCl â‰¤50 mL/min [see <span class="Italics">Dosage and Administration (<a href="#s6">2</a>)</span>].
</p>
<p>Creatinine clearance was estimated from serum creatinine based on the Cockcroft-Gault formula:
</p>
<dl>
<dt>Â 
</dt>
<dd>CrCl = <span class="Underline">[140 â€“ age (years)] x ideal body weight (kg)*</span> {x 0.85 for female patients}<br>Â  Â  Â  Â  Â  Â  Â  Â  [72 x serum creatinine (mg/dL)]
</dd>
<dt>Â 
</dt>
<dd>
<br>*Use actual body weight if &lt; ideal body weight (IBW)<br>IBW (male) = 50 kg + 0.9 kg/cm over 152 cm height<br>IBW (female) = 45.5 kg + 0.9 kg/cm over 152 cm height
</dd>
</dl>
<p>Following administration of a single dose of VIBATIV 7.5 mg/kg to subjects with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, approximately 5.9% of the administered dose of telavancin was recovered in the dialysate following 4 hours of hemodialysis. The effects of peritoneal dialysis have not been studied.
</p>
<p>Following a single intravenous dose of VIBATIV 7.5 mg/kg, the clearance of hydroxypropyl-beta-cyclodextrin was reduced in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, resulting in a higher exposure to hydroxypropyl-beta-cyclodextrin. In subjects with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the mean clearance values were 38%, 59%, and 82% lower, respectively, compared with subjects with normal renal function. Multiple infusions of VIBATIV may result in accumulation of hydroxypropyl-beta-cyclodextrin.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s68"></a><a name="section-11.3.9"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>The pharmacokinetics of telavancin were not altered in subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (n= 8, Child-Pugh B) compared with healthy subjects with normal hepatic function matched for gender, age, and weight. The pharmacokinetics of telavancin have not been evaluated in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s69"></a><a name="section-11.3.10"></a><p></p>
<p class="First"><span class="Underline">Drug Interactions</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s70"></a><a name="section-11.3.11"></a><p></p>
<p class="First"><span class="Italics">In Vitro</span></p>
<p>The inhibitory activity of telavancin against the following CYP 450 enzymes was evaluated in human liver microsomes: CYP 1A2, 2C9, 2C19, 2D6, and 3A4/5. Telavancin inhibited CYP 3A4/5 at potentially clinically relevant concentrations. Upon further evaluation in a Phase 1 clinical trial, telavancin was found not to inhibit the metabolism of midazolam, a sensitive CYP3A substrate (see below).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s71"></a><a name="section-11.3.12"></a><p></p>
<p class="First"><span class="Italics">Midazolam</span></p>
<p>The impact of telavancin on the pharmacokinetics of midazolam (CYP 3A4/5 substrate) was evaluated in 16 healthy adult subjects following administration of a single dose of VIBATIV 10 mg/kg, intravenous midazolam 1 mg, and both. The results showed that telavancin had no impact on the pharmacokinetics of midazolam and midazolam had no effect on the pharmacokinetics of telavancin.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s72"></a><a name="section-11.3.13"></a><p></p>
<p class="First"><span class="Italics">Aztreonam</span></p>
<p>The impact of telavancin on the pharmacokinetics of aztreonam was evaluated in 11 healthy adult subjects following administration of a single dose of VIBATIV 10 mg/kg, aztreonam 2Â g, and both. Telavancin had no impact on the pharmacokinetics of aztreonam and aztreonam had no effect on the pharmacokinetics of telavancin. No dosage adjustment of telavancin or aztreonam is recommended when both drugs are coadministered.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s73"></a><a name="section-11.3.14"></a><p></p>
<p class="First"><span class="Italics">Piperacillin-tazobactam</span></p>
<p>The impact of telavancin on the pharmacokinetics of piperacillin-tazobactam was evaluated in 12 healthy adult subjects following administration of a single dose of VIBATIV 10 mg/kg, piperacillin-tazobactam 4.5 g, and both. Telavancin had no impact on the pharmacokinetics of piperacillin-tazobactam and piperacillin-tazobactam had no effect on the pharmacokinetics of telavancin. No dosage adjustment of telavancin or piperacillin-tazobactam is recommended when both drugs are coadministered.
</p>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="s74"></a><a name="section-11.4"></a><p></p>
<h2>12.4 Microbiology
</h2>
<p class="First">Telavancin is a semisynthetic, lipoglycopeptide antibiotic. Telavancin exerts concentration-dependent, bactericidal activity against Gram-positive organisms <span class="Italics">in vitro</span>, as demonstrated by time-kill assays and MBC/MIC (minimum bactericidal concentration/<span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span>) ratios using broth dilution methodology. <span class="Italics">In vitro</span> studies demonstrated a telavancin post-antibiotic effect ranging from 1 to 6 hours against <span class="Italics">S.Â aureus</span> and other Gram-positive pathogens.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s75"></a><a name="section-11.4.1"></a><p></p>
<p class="First"><span class="Underline">Mechanism of Action</span></p>
<p>Telavancin inhibits cell wall biosynthesis by binding to late-stage peptidoglycan precursors, including lipid II.  Telavancin also binds to the bacterial membrane and disrupts membrane barrier function.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s76"></a><a name="section-11.4.2"></a><p></p>
<p class="First"><span class="Underline">Interactions with Other Antibacterial Drugs</span></p>
<p><span class="Italics">In vitro</span> investigations demonstrated no antagonism between telavancin and amikacin, aztreonam, cefepime, ceftriaxone, ciprofloxacin, gentamicin, imipenem, meropenem, oxacillin, piperacillin/tazobactam, rifampin, and trimethoprim/sulfamethoxazole when tested in various combinations against telavancin-susceptible staphylococci, streptococci, and enterococci. This information is not available for other bacteria.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s77"></a><a name="section-11.4.3"></a><p></p>
<p class="First"><span class="Underline">Cross-Resistance</span></p>
<p>Some vancomycin-resistant enterococci have a reduced susceptibility to telavancin. There is no known cross-resistance between telavancin and other classes of antibacterial drugs.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s78"></a><a name="section-11.4.4"></a><p></p>
<p class="First"><span class="Underline">Antibacterial Activity</span></p>
<p>Telavancin has been shown to be active against most isolates of the following microorganisms both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the Indications and Usage section [see <span class="Italics">Indications and Usage (<a href="#s3">1</a>)</span>]:
</p>
<p><span class="Underline">Facultative Gram-Positive Microorganisms</span></p>
<dl>
<dt>Â 
</dt>
<dd>
<span class="Italics">Staphylococcus aureus</span> (including methicillin-resistant isolates)
</dd>
<dt>Â 
</dt>
<dd>
<span class="Italics">Entero</span>c<span class="Italics">occus faecalis</span> (vancomycin-susceptible isolates only)
</dd>
<dt>Â 
</dt>
<dd><span class="Italics">Streptococcus agalactiae</span></dd>
<dt>Â 
</dt>
<dd>
<span class="Italics">Streptococcus anginosus</span> group (includes <span class="Italics">S. anginosus, S. intermedius,</span> and <span class="Italics">S.Â constellatus</span>)
</dd>
<dt>Â 
</dt>
<dd><span class="Italics">Streptococcus pyogenes</span></dd>
</dl>
<p>Greater than 90% of the following microorganisms exhibit an <span class="Italics">in vitro</span> MIC less than or equal to the telavancin-susceptible breakpoint for organisms of similar genus shown in <a href="#t9">TableÂ 9</a>. The safety and effectiveness of telavancin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials.
</p>
<p><span class="Underline">Facultative Gram-Positive Microorganisms</span></p>
<dl>
<dt>Â 
</dt>
<dd>
<span class="Italics">Enterococcus faecium</span> (vancomycin-susceptible isolates only)
</dd>
<dt>Â 
</dt>
<dd><span class="Italics">Staphylococcus haemolyticus</span></dd>
<dt>Â 
</dt>
<dd>
<span class="Italics">Streptococcus dysgalactiae</span> subsp. <span class="Italics">equisimilis</span>
</dd>
<dt>Â 
</dt>
<dd><span class="Italics">Staphylococcus epidermidis</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s79"></a><a name="section-11.4.5"></a><p></p>
<p class="First"><span class="Underline">Susceptibility Test Methods</span></p>
<p>When available, the clinical microbiology laboratory should provide cumulative results of the <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antimicrobial drug.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s80"></a><a name="section-11.4.6"></a><p></p>
<p class="First"><span class="Italics">Dilution technique</span></p>
<p>Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure [see <span class="Italics">References (<a href="#s89">15</a>)</span>]. Standardized procedures are based on a broth dilution method or equivalent with standardized inoculum concentrations and standardized concentrations of telavancin powder. The test method treats telavancin as a water-insoluble agent. Dimethyl sulfoxide is used as solvent and diluent, and the cation-adjusted Mueller Hinton Broth test medium is supplemented with polysorbate 80 to a final concentration of 0.002%. Telavancin should not be tested by the agar dilution method.  The MIC values should be interpreted according to the criteria provided in <a href="#t9">TableÂ 9</a>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s81"></a><a name="section-11.4.7"></a><p></p>
<p class="First"><span class="Italics">Diffusion technique</span></p>
<p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure requires the use of standardized inoculum concentrations [see <span class="Italics">References (<a href="#s89">15</a>)</span>]. This procedure uses paper disks impregnated with 30 mcg of telavancin to test the susceptibility of microorganisms to telavancin. The disk diffusion interpretive criteria are provided in <a href="#t9">TableÂ 9</a>.
</p>
<a name="t9"></a><table width="100%">
<caption><span>TableÂ 9: Susceptibility Interpretive Criteria for Telavancin
</span></caption>
<col align="left" width="42.522%">
<col align="left" width="9.584%">
<col align="left" width="9.584%">
<col align="left" width="9.584%">
<col align="left" width="9.584%">
<col align="left" width="9.584%">
<col align="left" width="9.556%">
<tfoot><tr class="First Last"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">1</span> The current absence of resistant isolates precludes defining any results other than â€œsusceptible.â€? Isolates yielding results other than susceptible should be subjected to additional testing.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="3" valign="middle"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="6" valign="top">
<span class="Bold">Susceptibility Interpretive Criteria</span><span class="Bold"><span class="Sup">1</span></span>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" colspan="3" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentration</span> (mcg/mL)</span></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top"><span class="Bold">Disk Diffusion Zone Diameter (mm)</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">S</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">I</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">R</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">S</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">I</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">R</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Italics">Staphylococcus aureus
</span><br>(including methicillin-resistant isolates)
</td>
<td class="Botrule Rrule" align="center" valign="top">â‰¤ 0.12
</td>
<td class="Botrule Rrule" align="center" valign="top">--
</td>
<td class="Botrule Rrule" align="center" valign="top">--
</td>
<td class="Botrule Rrule" align="center" valign="top">â‰¥ 15
</td>
<td class="Botrule Rrule" align="center" valign="top">--
</td>
<td class="Botrule Rrule" align="center" valign="top">--
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Italics">Streptococcus pyogenes</span><br><span class="Italics">Streptococcus agalactiae</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤ 0.12
</td>
<td class="Botrule Rrule" align="center" valign="middle">--
</td>
<td class="Botrule Rrule" align="center" valign="middle">--
</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¥ 15
</td>
<td class="Botrule Rrule" align="center" valign="middle">--
</td>
<td class="Botrule Rrule" align="center" valign="middle">--
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Italics">Streptococcus anginosus group</span></td>
<td class="Botrule Rrule" align="center" valign="top">â‰¤ 0.06
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">â‰¥ 15
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Italics">Enterococcus faecalis</span> (vancomycin-susceptible isolates only)
</td>
<td class="Botrule Rrule" align="center" valign="top">â‰¤ 0.25
</td>
<td class="Botrule Rrule" align="center" valign="top">--
</td>
<td class="Botrule Rrule" align="center" valign="top">--
</td>
<td class="Botrule Rrule" align="center" valign="top">â‰¥ 15
</td>
<td class="Botrule Rrule" align="center" valign="top">--
</td>
<td class="Botrule Rrule" align="center" valign="top">--
</td>
</tr>
</tbody>
</table>
<p>A report of â€œsusceptible" indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound in the blood reaches the concentrations usually achievable.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s82"></a><a name="section-11.4.8"></a><p></p>
<p class="First"><span class="Italics">Quality Control</span></p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to monitor the performance of the supplies and reagents used in the assay, and the techniques of the individuals performing the test [see <span class="Italics">References (<a href="#s89">15</a>)</span>]. Standard telavancin powder should provide the range of values noted in <a href="#t10">TableÂ 10</a>.
</p>
<p>Quality control microorganisms are specific <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of organisms with intrinsic biological properties relating to resistance mechanisms and their genetic expression within bacteria; the specific <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> used for microbiological quality control are not clinically significant.
</p>
<a name="t10"></a><table width="100%">
<caption><span>TableÂ 10: Acceptable Quality Control Ranges for Telavancin to be used in Validation of Susceptibility Test Results
</span></caption>
<col align="left" width="33.344%">
<col align="left" width="33.344%">
<col align="left" width="33.311%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="bottom"></th>
<th class="Botrule Rrule Toprule" align="center" colspan="2" valign="bottom"><span class="Bold">Acceptable Quality Control Ranges</span></th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">1</span> This organism may be used for validation of susceptibility test results when testing <span class="Italics">Streptococcus</span> spp. other than <span class="Italics">S. pneumoniae</span></p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="center" valign="top">Â 
</td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentration</span> (mcg/mL)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Disk Diffusion Zone Diameter (mm)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Italics">Enterococcus faecalis<br></span>ATCC 29212
</td>
<td class="Botrule Rrule" align="center" valign="top">0.03 â€“ 0.12
</td>
<td class="Botrule Rrule" align="center" valign="top">Not applicable
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Italics">Staphylococcus aureus
</span><br>ATCC 29213
</td>
<td class="Botrule Rrule" align="center" valign="top">0.03 - 0.12
</td>
<td class="Botrule Rrule" align="center" valign="top">Not applicable
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Italics">Staphylococcus aureus
</span><br>ATCC 25923
</td>
<td class="Botrule Rrule" align="center" valign="top">Not applicable
</td>
<td class="Botrule Rrule" align="center" valign="top">16-20
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Italics">Streptococcus pneumoniae</span><br>ATCC 49619<span class="Sup">1</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.004 â€“ 0.015
</td>
<td class="Botrule Rrule" align="center" valign="top">17-24
</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s83"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s84"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Long-term studies in animals to determine the carcinogenic potential of telavancin have not been performed.
</p>
<p>Neither mutagenic nor clastogenic potential of telavancin was found in a battery of tests including: assays for mutagenicity (Ames bacterial reversion), an <span class="Italics">in vitro</span> chromosome aberration assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and an <span class="Italics">in vivo</span> mouse micronucleus assay.
</p>
<p>Telavancin did not affect the fertility or reproductive performance of adult male rats (exposed to telavancin for at least 4 weeks prior to mating) or female rats (exposed to telavancin for at least 2 weeks prior to mating).
</p>
<p>Male rats given telavancin for 6 weeks, at exposures similar to those measured in clinical studies, displayed altered sperm parameters that were reversible following an 8-week recovery period.
</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="s85"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology
</h2>
<p class="First">Two-week administration of telavancin in rats produced minimal renal tubular vacuolization with no changes in BUN or creatinine. These effects were not seen in studies conducted in dogs for similar duration. Four weeks of treatment resulted in reversible elevations in BUN and/or creatinine in association with renal tubular degeneration that further progressed following 13 weeks of treatment.
</p>
<p>These effects occurred at exposures (based on AUCs) that were similar to those measured in clinical trials.
</p>
<p>The potential effects of continuous venovenous hemofiltration (CVVH) on the clearance of telavancin were examined in an <span class="Italics">in vitro</span> model using bovine blood. Telavancin was cleared by CVVH and the clearance of telavancin increased with increasing ultrafiltration rate [see <span class="Italics">Overdosage (<a href="#s53">10</a>)</span>].
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s86"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL TRIALS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s87"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
</h2>
<p class="First">Adult patients with clinically documented complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (cSSSI) were enrolled in two randomized, multinational, multicenter, double-blinded trials (Trial 1 and Trial 2) comparing VIBATIV (10 mg/kg IV every 24 hours) with vancomycin (1 g IV every 12 hours) for 7 to 14 days. Vancomycin dosages could be adjusted per site-specific practice. Patients could receive concomitant aztreonam or metronidazole for suspected Gram-negative and anaerobic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, respectively. These trials were identical in design, enrolling approximately 69% of their patients from the United States.
</p>
<p>The trials enrolled adult patients with cSSSI with suspected or confirmed MRSA as the primary cause of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. The all-treated efficacy (ATe) population included all patients who received any amount of study medication according to their randomized treatment group and were evaluated for efficacy. The clinically evaluable population (CE) included patients in the ATe population with sufficient adherence to the protocol.
</p>
<p>The ATe population consisted of 1,794 patients. Of these, 1,410 (79%) patients were clinically evaluable (CE). Patient baseline <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> types were well-balanced between treatment groups and are presented in <a href="#t11">TableÂ 11</a>.
</p>
<a name="t11"></a><table width="100%">
<caption><span>TableÂ 11: Baseline <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> Types in Patients in cSSSI Trials 1 and 2 â€“ ATe Population
</span></caption>
<col align="left" width="37.154%">
<col align="left" width="31.423%">
<col align="left" width="31.423%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">1</span> Includes all patients randomized, treated, and evaluated for efficacy
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">VIBATIV<br>(N=884)</span><span class="Bold"><span class="Sup">1</span></span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">Vancomycin<br>(N=910)</span><span class="Bold"><span class="Sup">1</span></span>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="middle">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Major <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">375 (42.4%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">397 (43.6%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Deep/Extensive <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">Cellulitis</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">309 (35.0%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">337 (37.0%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4153877" conceptname="Post-traumatic wound infection">Wound Infection</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">139 (15.7%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">121 (13.3%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Infected <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">45 (5.1%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">46 (5.1%)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Infected Burn
</td>
<td class="Botrule Rrule" align="center" valign="middle">16 (1.8%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">9 (1.0%)
</td>
</tr>
</tbody>
</table>
<p>The primary efficacy endpoints in both trials were the clinical cure rates at a follow-up (TestÂ of Cure) visit in the ATe and CE populations. Clinical cure rates in Trials 1 and 2 are displayed for the ATe and CE population in <a href="#t12">TableÂ 12</a>.
</p>
<a name="t12"></a><table width="100%">
<caption><span>TableÂ 12: Clinical Cure at Test-of-Cure in cSSSI Trials 1 and 2 â€“ ATe and CE Populations
</span></caption>
<col align="left" width="4.956%">
<col align="left" width="15.883%">
<col align="left" width="15.926%">
<col align="left" width="15.755%">
<col align="left" width="15.841%">
<col align="left" width="15.855%">
<col align="left" width="15.783%">
<tfoot><tr class="First Last"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Bold"><span class="Sup">1</span></span>95% CI computed using a continuity correction
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3" valign="middle">Â 
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="bottom"><span class="Bold">Trial 1</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="bottom"><span class="Bold">Trial 2</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">VIBATIV</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Vancomycin</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Difference</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">VIBATIV</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Vancomycin</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Difference</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">% (n/N)</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">% (n/N)</span></td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">(95% CI)</span><span class="Bold"><span class="Sup">1</span></span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">% (n/N)</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">% (n/N)</span></td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">(95% CI)</span><span class="Bold"><span class="Sup">1</span></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle"><span class="Bold">ATe</span></td>
<td class="Botrule Rrule" align="center" valign="top">72.5%
</td>
<td class="Botrule Rrule" align="center" valign="top">71.6%
</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="middle">0.9<br>(-5.3, 7.2)
</td>
<td class="Botrule Rrule" align="center" valign="top">74.7%
</td>
<td class="Botrule Rrule" align="center" valign="top">74.0%
</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="middle">0.7<br>(-5.1, 6.5)
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">(309/426)
</td>
<td class="Botrule Rrule" align="center" valign="top">(307/429)
</td>
<td class="Botrule Rrule" align="center" valign="top">(342/458)
</td>
<td class="Botrule Rrule" align="center" valign="top">(356/481 )
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle"><span class="Bold">CE</span></td>
<td class="Botrule Rrule" align="center" valign="top">84.3%
</td>
<td class="Botrule Rrule" align="center" valign="top">82.8%
</td>
<td class="Rrule" align="center" valign="middle">1.5
</td>
<td class="Botrule Rrule" align="center" valign="top">83.9%
</td>
<td class="Botrule Rrule" align="center" valign="top">87.7%
</td>
<td class="Rrule" align="center" valign="middle">-3.8
</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center" valign="top">(289/343)
</td>
<td class="Botrule Rrule" align="center" valign="top">(288/348)
</td>
<td class="Botrule Rrule" align="center" valign="middle">(-4.3, 7.3)
</td>
<td class="Botrule Rrule" align="center" valign="top">(302/360)
</td>
<td class="Botrule Rrule" align="center" valign="top">(315/359 )
</td>
<td class="Botrule Rrule" align="center" valign="middle">(-9.2, 1.5)
</td>
</tr>
</tbody>
</table>
<p>The cure rates by pathogen for the microbiologically evaluable (ME) population are presented in <a href="#t13">TableÂ 13</a>.
</p>
<a name="t13"></a><table width="100%">
<caption><span>TableÂ 13: Clinical Cure Rates at the Test-of-Cure for the Most Common Pathogens in cSSSI Trials 1 and 2 â€“ ME Population<span class="Sup">1</span></span></caption>
<col align="left" width="43.267%">
<col align="left" width="28.367%">
<col align="left" width="28.367%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">1</span> The ME population included patients in the CE population who had Gram-positive pathogens isolated at baseline and had central identification and susceptibility of the microbiological isolate(s).
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">VIBATIV<br>% (n/N)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Vancomycin<br>% (n/N)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Italics">Staphylococcus aureus</span><br>(MRSA)
</td>
<td class="Botrule Rrule" align="center" valign="top">87.0%<br>(208/239)
</td>
<td class="Botrule Rrule" align="center" valign="top">85.9%<br>(225/262)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Italics">Staphylococcus aureus</span><br>(MSSA)
</td>
<td class="Botrule Rrule" align="center" valign="top">82.0%<br>(132/161)
</td>
<td class="Botrule Rrule" align="center" valign="top">85.1%<br>(131/154)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Italics">Enterococcus faecalis</span></td>
<td class="Botrule Rrule" align="center" valign="top">95.6%<br>(22/23)
</td>
<td class="Botrule Rrule" align="center" valign="top">80.0%<br>(28/35)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Italics">Streptococcus pyogenes</span></td>
<td class="Botrule Rrule" align="center" valign="top">84.2%<br>(16/19)
</td>
<td class="Botrule Rrule" align="center" valign="top">90.5%<br>(19/21)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Italics">Streptococcus agalactiae</span></td>
<td class="Botrule Rrule" align="center" valign="top">73.7%<br>(14/19)
</td>
<td class="Botrule Rrule" align="center" valign="top">86.7%<br>(13/15)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Italics">Streptococcus anginosus<br></span>group
</td>
<td class="Botrule Rrule" align="center" valign="top">76.5%<br>(13/17)
</td>
<td class="Botrule Rrule" align="center" valign="top">100.0%<br>(9/9)
</td>
</tr>
</tbody>
</table>
<p>In the two cSSSI trials, clinical cure rates were similar across gender and race. Clinical cure rates in the VIBATIV clinically evaluable (CE) population were lower in patients â‰¥65 years of age compared with those &lt;65 years of age. A decrease of this magnitude was not observed in the vancomycin CE population. Clinical cure rates in the VIBATIV CE population &lt;65Â years of age were 503/581 (87%) and in those â‰¥65 years were 88/122 (72%). In the vancomycin CE population clinical cure rates in patients &lt;65 years of age were 492/570 (86%) and in those â‰¥65 years was 111/137 (82%). Clinical cure rates in the VIBATIV-treated patients were lower in patients with baseline CrCl â‰¤50 mL/min compared with those with CrCl &gt;50Â mL/min. A decrease of this magnitude was not observed in the vancomycin-treated patients [see <span class="Italics">Warnings and Precautions (<a href="#s17">5.2</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s88"></a><a name="section-13.2"></a><p></p>
<h2>14.2 HABP/VABP
</h2>
<p class="First">Adult patients with hospital-acquired and ventilator-associated <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> were enrolled in two randomized, parallel-group, multinational, multicenter, double-blinded trials of identical design comparing VIBATIV (10 mg/kg IV every 24Â hours) with vancomycin (1Â g IV every 12Â hours) for 7 to 21 days. Vancomycin dosages could be adjusted for body weight and/or renal function per local guidelines. Patients could receive concomitant aztreonam or metronidazole for suspected Gram-negative and anaerobic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, respectively. The addition of piperacillin/tazobactam was also permitted for coverage of Gram-negative organisms if resistance to aztreonam was known or suspected. Patients with known or suspected <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to methicillin-resistant <span class="Italics">Staphylococcus aureus</span> were enrolled in the studies.
</p>
<p>Of the patients enrolled across both trials, 64% were male and 70% were white.The mean age was 63 years. At baseline, more than 50% were admitted to an intensive care unit, about 23% had <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>, about 29% had ventilator-associated <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and about 6% had <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>. Demographic and baseline characteristics were generally well-balanced between treatment groups; however, there were differences between HABP/VABP Trial 1 and HABP/VABP Trial 2 with respect to a baseline history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (31% in Trial 1, 21% in Trial 2) and baseline <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (CrClÂ â‰¤Â 50Â mL/min) (36% in Trial 1, 27% in Trial 2).
</p>
<p>All-cause mortality was evaluated because there is historical evidence of treatment effect for this endpoint. This was a protocol pre-specified secondary endpoint. The 28-day all-cause mortality outcomes(overall and by baseline creatinine clearance categorization) in the group of patients who had at least one baseline Gram-positive respiratory pathogen are shown in <a href="#t14">TableÂ 14</a>. This group of patients included those who had mixed Gram-positive/Gram-negative <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.
</p>
<a name="t14"></a><table width="100%">
<caption><span>TableÂ 14: All-Cause Mortality at Day 28 in Patients with at least One Baseline Gram-Positive Pathogen
</span></caption>
<col align="left" width="22.687%">
<col align="left" width="14.769%">
<col align="left" width="13.586%">
<col align="left" width="17.686%">
<col align="left" width="13.586%">
<col align="left" width="17.686%">
<tfoot><tr class="First Last"><td align="left" colspan="6" valign="top"><p class="First Footnote"><span class="Sup">a</span>Mortality rates are based on Kaplan-Meier estimates at Study Day 28. There were 84 patients (5.6%) whose survival statuses were not known up to 28 days after initiation of study drug and were considered censored at the last day known to be alive. Thirty-five of these patients were treated with VIBATIV and 45 were treated with vancomycin.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="middle"></td>
<td class="Rrule Toprule" align="left" valign="middle"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="middle"><span class="Bold">Trial 1</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="middle"><span class="Bold">Trial 2</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">VIBATIV</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Vancomycin</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">VIBATIV</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Vancomycin</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="middle">All Patients
</td>
<td class="Botrule Rrule" align="left" valign="middle">Mortality<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">28.7%<br>N=187
</td>
<td class="Botrule Rrule" align="center" valign="middle">24.3%<br>N=180
</td>
<td class="Botrule Rrule" align="center" valign="middle">24.3%<br>N=224
</td>
<td class="Botrule Rrule" align="center" valign="middle">22.3%<br>N=206
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Difference<br>(95%Â CI)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">4.4%<br>(-4.7%, 13.5%)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">2.0%<br>(-6.1%, 10%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="middle">CrClÂ â‰¤Â 50Â mL/min
</td>
<td class="Botrule Rrule" align="left" valign="middle">Mortality<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">41.8%<br>N=63
</td>
<td class="Botrule Rrule" align="center" valign="middle">35.4%<br>N=68
</td>
<td class="Botrule Rrule" align="center" valign="middle">43.9%<br>N=53
</td>
<td class="Botrule Rrule" align="center" valign="middle">29.6%<br>N=58
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Difference<br>(95%Â CI)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">6.4%<br>(-10.4, 23.2)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">14.3%<br>(-3.6, 32.2)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="middle">CrClÂ &gt;Â 50Â mL/min
</td>
<td class="Botrule Rrule" align="left" valign="middle">Mortality<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">22.0%<br>N=124
</td>
<td class="Botrule Rrule" align="center" valign="middle">17.6%<br>N=112
</td>
<td class="Botrule Rrule" align="center" valign="middle">18.2%<br>N=171
</td>
<td class="Botrule Rrule" align="center" valign="middle">19.3%<br>N=148
</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top">Difference<br>(95%Â CI)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">4.4%<br>(-5.9, 14.7)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">-1.1%<br>(-9.8, 7.6)
</td>
</tr>
</tbody>
</table>
<p>The protocol-specified analysis included clinical cure rates at the TOC (7Â toÂ 14 days after the last dose of study drug) in the co-primary All-Treated (AT) and Clinically Evaluable (CE) populations (<a href="#t15">TableÂ 15</a>). Clinical cure was determined by resolution of signs and symptoms, no further antibacterial therapy for HABP/VABP after end-of-treatment, and improvement or no progression of baseline radiographic findings. However, the quantitative estimate of treatment effect for this endpoint has not been established.
</p>
<a name="t15"></a><table width="100%">
<caption><span>TableÂ 15: Clinical Response Rates in Trials 1 and 2 â€“ AT and CE Populations
</span></caption>
<col align="left" width="27.265%">
<col align="left" width="15.743%">
<col align="left" width="20.624%">
<col align="left" width="15.743%">
<col align="left" width="20.624%">
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">a</span>All-Treated (AT) Population: Patients who received at least one dose of study medication
</p></td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">b</span>Clinically Evaluable (CE) Population: Patients who were clinically evaluable
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="middle"><span class="Bold">Trial 1</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="middle"><span class="Bold">Trial 2</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">VIBATIV</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Vancomycin</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">VIBATIV</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Vancomycin</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="middle">AT<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">57.5%<br>(214/372)
</td>
<td class="Botrule Rrule" align="center" valign="middle">59.1%<br>(221/374)
</td>
<td class="Botrule Rrule" align="center" valign="middle">60.2%<br>(227/377)
</td>
<td class="Botrule Rrule" align="center" valign="middle">60.0%<br>(228/380)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">Difference<br>(95% CI)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">-1.6%<br>(-8.6%, 5.5%)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">0.2%<br>(-6.8%, 7.2%)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="middle">CE<span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">83.7%<br>(118/141)
</td>
<td class="Botrule Rrule" align="center" valign="middle">80.2%<br>(138/172)
</td>
<td class="Botrule Rrule" align="center" valign="middle">81.3%<br>(139/171)
</td>
<td class="Botrule Rrule" align="center" valign="middle">81.2%<br>(138/170)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">Difference<br>(95% CI)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">3.5%<br>(-5.1%, 12.0%)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">0.1%<br>(-8.2%, 8.4%)
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s89"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES
</h1>
<ol class="Arabic">
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Ninth Edition</span>. CLSI document M07-A9, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.
</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard â€“ Eleventh Edition.</span> CLSI document M02-A11, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.
</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fourth Informational Supplement</span>, CLSI document M100-S24, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2014.
</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s90"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<ul class="Disc">
<li>Cartons of 10 individually packaged 250 mg single-dose vials (NDC 62847-002-01)
</li>
<li>Cartons of 10 individually packaged 750 mg single-dose vials (NDC 62847-001-01)
</li>
</ul>
<p class="First">Store original packages at refrigerated temperatures of 2 to 8Â°C (35 to 46 Â°F). Excursions to ambient temperatures (up to 25 Â°C (77 Â°F)) are acceptable. Avoid excessive heat.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s91"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First"><span class="Italics">See <a href="#s97">Medication Guide</a>.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s92"></a><a name="section-16.1"></a><p></p>
<p class="First"><span class="Underline">Use During Pregnancy and By Women of Childbearing Potential</span></p>
<p>Women of childbearing potential (those who have <span class="Bold Underline">not</span> had: complete absence of menses for at least 24 months or medically confirmed <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, medically confirmed <span class="product-label-link" type="condition" conceptid="193739" conceptname="Ovarian failure">primary ovarian failure</span>, a history of hysterectomy, bilateral oophorectomy, or tubal ligation)  should:
</p>
<ul class="Disc">
<li>Be informed about the potential risk of fetal harm if VIBATIV is used during pregnancy
</li>
<li>Have a pregnancy test prior to administration of VIBATIV
</li>
<li>If not pregnant, use effective contraceptive methods to prevent pregnancy during VIBATIV treatment
</li>
<li>Notify their prescribing physician/ healthcare provider if they become pregnant during VIBATIV treatment
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s93"></a><a name="section-16.2"></a><p></p>
<p class="First"><span class="Underline">Pregnancy Registry</span></p>
<p>There is a pregnancy registry that monitors pregnancy outcomes in women exposed to VIBATIV during pregnancy. Physicians are encouraged to register pregnant patients, or pregnant women may enroll themselves in the pregnancy registry by calling 1-855-633-8479.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s94"></a><a name="section-16.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics that usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as 2 or more months after having received the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s95"></a><a name="section-16.4"></a><p></p>
<p class="First"><span class="Underline">Correct Use of Antibacterial Drugs</span></p>
<p>Patients should be counseled that antibacterial drugs including VIBATIV should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When VIBATIV is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of immediate treatment, and (2) increase the likelihood that the bacteria will develop resistance and will not be treatable by VIBATIV or other antibacterial drugs in the future.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s96"></a><a name="section-16.5"></a><p></p>
<p class="First"><span class="Underline">Common Adverse Effects</span></p>
<p>Patients should be informed about the common adverse effects of VIBATIV including <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and foamy urine. Patients should be instructed to inform their healthcare provider if they develop any unusual symptom, or if any known symptom persists or worsens. Patients should be instructed to inform their healthcare provider of any other medications they are currently taking with VIBATIV, including over-the-counter medications.
</p>
<p><span class="Bold">Manufactured by:<br></span>Theravance Biopharma Antibiotics, Inc.

</p>
<p><span class="Bold">Marketed by:</span><br>Theravance Biopharma US, Inc.<br>South San Francisco, CA  94080
</p>
<p>US Patent Nos. 6,635,618 B2; 6,858,584 B2; 6,872,701 B2; 7,008,923 B2; 7,208,471 B2; 7,351,691 B2; 7,531,623 B2; 7,544,364 B2; 7,700,550 B2; 8,101,575 B2; 8,158,580 B2.
</p>
<p>THERAVANCE<span class="Sup">Â®</span>, the Cross/Star logo, VIBATIV<span class="Sup">Â®</span> and the VIBATIV<span class="Sup">Â®</span> logo are registered trademarks of the Theravance Biopharma group of companies.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="s97"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE<br>VIBATIV</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">(vy-'ba-tiv)<br>(telavancin) <br>for injection</span></p>
<p>Read this Medication Guide before you receive VIBATIV. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
</p>
<p><a name="p01"></a><span class="Bold">What is the most important information I should know about VIBATIV?</span></p>
<p><span class="Bold">VIBATIV can cause serious side effects, including:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> VIBATIV was associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> compared to vancomycin in people who already had kidney problems and were treated for bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> that you can get when you are in the hospital.
</li>
<li>
<span class="Bold">New or worsening kidney problems.</span> Your healthcare provider should do a blood test to check your kidneys before you start, while you receive, and after you stop receiving VIBATIV.
</li>
<li>
<span class="Bold">VIBATIV may harm your unborn baby.  Women who can become pregnant should have a blood pregnancy test before receiving VIBATIV.</span><ul class="Square">
<li>Talk to your healthcare provider if you are pregnant or plan to become pregnant. Your healthcare provider will decide if VIBATIV is the right medicine for you.
</li>
<li>Women who can become pregnant should use effective birth control (contraception) while receiving VIBATIV.
</li>
<li>If you become pregnant while receiving VIBATIV, tell your healthcare provider right away. Talk to your healthcare provider about taking part in the VIBATIV Pregnancy Registry.  This is a study to learn how VIBATIV affects pregnancy and babies. You can enroll in this registry by calling 1-855-633-8479.
</li>
</ul>
</li>
</ul>
<p><span class="Bold">What is VIBATIV?</span></p>
<p>VIBATIV is a prescription antibacterial medicine used alone, or with other medicines, to treat adults with certain types of germs (bacteria) that cause:
</p>
<ul class="Disc">
<li>Serious <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span>
</li>
<li>Hospital-Acquired Bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> (HABP)
</li>
<li>Ventilator-Associated Bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> (VABP)
</li>
</ul>
<p>It is not known if VIBATIV is safe or effective in children under 18 years of age.
</p>
<p><span class="Bold">Who should not take VIBATIV?</span></p>
<p><span class="Bold">Do not take VIBATIV if you:</span></p>
<ul class="Disc"><li>are allergic to telavancin or any of the ingredients in VIBATIV. See the end of this Medication Guide for a complete list of ingredients in VIBATIV.
</li></ul>
<p><span class="Bold">What should I tell my healthcare provider before receiving VIBATIV?</span></p>
<p>Before you receive VIBATIV, tell your healthcare provider if you:
</p>
<ul class="Disc">
<li>have had a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to VIBATIV or vancomycin
</li>
<li>have kidney problems
</li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>
</li>
<li>have or have had heart problems, including QTc prolongation or a family history of it
</li>
<li>have high blood pressure
</li>
<li>have any other medical conditions
</li>
<li>are breastfeeding or plan to breastfeed.  It is not known if VIBATIV passes into breast milk. You and your healthcare provider should decide if you will breastfeed while receiving VIBATIV.
</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins, and herbal supplements. VIBATIV and other medicines can affect each other causing side effects.
</p>
<p>Especially tell your healthcare provider if you take:
</p>
<ul class="Disc">
<li>a Non-Steroidal Anti-Inflammatory Drug (NSAID)
</li>
<li>certain blood pressure medicines called ACE Inhibitors or ARBs
</li>
<li>water pills (diuretics)
</li>
<li>a blood thinner
</li>
<li>medicine to control your heart rate or rhythm (antiarrhythmics)
</li>
</ul>
<p>Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure.
</p>
<p>Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.
</p>
<p><span class="Bold">How will I receive VIBATIV?</span></p>
<ul class="Disc">
<li>VIBATIV is given by your healthcare provider through a needle placed into your vein (IV infusion) slowly over 1 hour, 1 time each day, for 7 to 21 days.
</li>
<li>
<span class="Bold">Do not</span> stop receiving VIBATIV unless your healthcare provider tells you to, even if you feel better.
</li>
<li>Your healthcare provider will do blood tests before you start and while you receive VIBATIV.
</li>
</ul>
<p><span class="Bold">What are the possible side effects of VIBATIV?</span></p>
<p><span class="Bold">VIBATIV may cause serious side effects, including:</span></p>
<p>See <span class="Bold">â€œ<a href="#p01">What is the most important information I should know about VIBATIV?</a>â€?</span></p>
<ul class="Disc">
<li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> can happen in people who take VIBATIV, even after only one dose. Stop taking VIBATIV and get emergency medical help right away if you get any of the following symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>
</li>
<li>trouble breathing or swallowing
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the lips, tongue, face
</li>
<li><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>
</li>
<li>rapid heartbeat
</li>
<li><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>
</li>
</ul>
</li>
<li>
<span class="Bold">Infusion-related reactions.</span> People who receive VIBATIV too quickly can have a certain type of <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> called â€œRed-man Syndromeâ€?. Signs and symptoms of Red-man Syndrome can include:<ul class="Circle">
<li>red color (<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>)
</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>
</li>
</ul>
</li>
<li>
<span class="Bold">Problems with the electrical system of your heart (QTc prolongation).</span> Tell your healthcare provider right away if you have a change in your heartbeat such as a fast or irregular heartbeat or if you had a <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> episode.
</li>
</ul>
<p>Call your healthcare provider right away if you have any of the serious side effects listed above.
</p>
<p><span class="Bold">The most common side effects of VIBATIV include:</span></p>
<ul class="Disc">
<li>change in your sense of taste
</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>
</li>
<li>foamy urine
</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
</li>
</ul>
<p>Tell your healthcare provider about any side effect that bothers you or that does not go away.  These are not all the possible side effects of VIBATIV.  For more information, ask your healthcare provider or pharmacist.
</p>
<p>Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088.
</p>
<p><span class="Bold">How should I store VIBATIV?</span></p>
<ul class="Disc">
<li>Store VIBATIV in the original package
</li>
<li>Keep VIBATIV refrigerated between 35Â°F to 46Â°F (2Â°C to 8Â°C)
</li>
<li>Keep out of heat
</li>
</ul>
<p>Keep VIBATIV and all medicines out of the reach of children.
</p>
<p><span class="Bold">General Information about the safe and effective use of VIBATIV.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.  Do not use VIBATIV for a condition for which it is not prescribed.
</p>
<p>This Medication Guide summarizes the most important information about VIBATIV. If you would like more information, talk with your healthcare provider.  You can ask your pharmacist or healthcare provider for information about VIBATIV that is written for health professionals.
</p>
<p>For more information, go to <span class="Underline">www.vibativ.com</span> or call 1-855-633-8479.
</p>
<p><span class="Bold">What are the ingredients in VIBATIV?</span></p>
<p><span class="Bold">Active ingredient:</span> telavancin hydrochloride
</p>
<p><span class="Bold">Inactive ingredients:</span> hydroxypropylbetadex, Ph. Eur (hydroxypropyl-beta-cyclodextrin), mannitol, sodium hydroxide and hydrochloric acid
</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration
</p>
<p><span class="Bold">Manufactured by:</span></p>
<p>Theravance Biopharma Antibiotics, Inc.
</p>
<p><span class="Bold">Marketed by:</span></p>
<p>Theravance Biopharma US, Inc.
						</p>
<p>South San Francisco, CA 94080
</p>
<p>VIBATIV<span class="Sup">Â®</span> is a registered trademark of the Theravance Biopharma group of companies.
</p>
<p>Revised: December 2014
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s98"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ 250 MG/VIAL UNIT CARTON</span></p>
<p>NDC 52118-002-01
</p>
<p>1 Carton containing 1 Vial of 250 mg
</p>
<p>Vibativ<span class="Sup">Â®</span></p>
<p>(telavancin hydrochloride)
</p>
<p>Equivalent to 250 mg telavancin per vial
</p>
<p>Rx only
</p>
<p>Theravance, Inc.
</p>
<div class="Figure">
<a name="f02"></a><img alt="PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ 250 MG/VIAL UNIT CARTON
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c09655ea-7af5-4443-a769-86e416214f59&amp;name=vib02-0018-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s99"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ 750 MG/VIAL UNIT CARTON</span></p>
<p>NDC 52118-001-01
</p>
<p>1 Carton containing 1 Vial of 750 mg
</p>
<p>Vibativ<span class="Sup">Â®</span></p>
<p>(telavancin hydrochloride)
</p>
<p>Equivalent to 750 mg telavancin per vial
</p>
<p>Rx only
</p>
<p>Theravance, Inc.
</p>
<div class="Figure">
<a name="f03"></a><img alt="PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ 750 MG/VIAL UNIT CARTON
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c09655ea-7af5-4443-a769-86e416214f59&amp;name=vib02-0018-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VIBATIVÂ 		
					</strong><br><span class="contentTableReg">telavancin hydrochloride injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:62847-001</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>telavancin hydrochloride</strong> (telavancin) </td>
<td class="formItem">telavancin</td>
<td class="formItem">15Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Hydroxypropylbetadex (0.58-0.68 MS)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:62847-001-01</td>
<td class="formItem">1  in 1 CONTAINER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022110</td>
<td class="formItem">11/05/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VIBATIVÂ 		
					</strong><br><span class="contentTableReg">telavancin hydrochloride injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:62847-002</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>telavancin hydrochloride</strong> (telavancin) </td>
<td class="formItem">telavancin</td>
<td class="formItem">15Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Hydroxypropylbetadex (0.58-0.68 MS)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:62847-002-01</td>
<td class="formItem">1  in 1 CONTAINER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">17 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022110</td>
<td class="formItem">11/05/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Theravance Biopharma Antibiotics, Inc.
							(815553225)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>90eb3a09-c412-421c-8a8a-185741ca0be8</div>
<div>Set id: c09655ea-7af5-4443-a769-86e416214f59</div>
<div>Version: 3</div>
<div>Effective Time: 20141015</div>
</div>
</div>Â <div class="DistributorName">Theravance Biopharma Antibiotics, Inc.</div></p>
</body></html>
